

Pranavaha: A Mechanistic Unified Framework Bridging Vedic Pranayama Science and Nicotinic Acetylcholine Receptor Pharmacology for Tobacco Cessation

A Mechanistic Hypothesis

Dr. Nischaya Nagori¹ and Divyanshu Singh Chouhan²

¹ Lead Author; Consciousness Researcher & Vedic Scholar, Vaidik Wisdom Series, Jodhpur, Rajasthan, India

² Software Engineer and Research Contributor, Jodhpur, Rajasthan, India

Website: vaidikwisdomseries.com

Correspondence: Dr. Nischaya Nagori

Abstract

Background: The global tobacco epidemic affects 1.2 billion users despite decades of pharmacotherapy development. Current cessation approaches (NRT, varenicline, bupropion) improve quit rates but leave substantial long-term relapse and a global funding gap of \$8.4 billion annually. We propose that this failure stems from a fundamental conceptual error: treating tobacco dependence as merely a neurochemical addiction rather than a systemic disruption of the body's innate cholinergic regulatory pathways.

Hypothesis: We present the **Pranavaha Framework** as a unified mechanistic model in which nicotine progressively desensitizes nicotinic acetylcholine receptors, disrupts the cholinergic anti-inflammatory pathway, and reinforces a maladaptive breath-linked ritual, while authentic pranayama and Vedic mantra practices are hypothesized to restore endogenous cholinergic signaling, autonomic regulation, and reward-pathway normalization without desensitization.

Evidence: We synthesize late-2025 structural biology, electrophysiology, fMRI, HRV, spirometry, and SARS-CoV-2 / alpha7 nAChR literature to build a coherent mechanistic case. The strongest support currently available in this workspace is literature-backed rather than locally reproduced computation.

Implications: The Pranavaha Protocol is framed here as a low-cost, culturally grounded cessation hypothesis with a plausible neural-immune basis and a clear pathway to computational and clinical testing, not as completed therapeutic proof.

Keywords: alpha7 nicotinic acetylcholine receptor, cholinergic anti-inflammatory pathway, pranayama, tobacco cessation, Ayurveda, Pranavaha Srotas, vagus nerve, Atharva Veda, Prana Suktam, nicotine desensitization, Pancha Kosha, Turiya, Kumbhaka, Tridosha, Kriya Yoga

1. Introduction

1.1 The Scale of Failure

The tobacco epidemic remains one of humanity's most persistent public health crises. As of 2024, approximately 1.3 billion adults globally continue to use tobacco products, of whom **7.7 million die annually** — **one person every four seconds** [1]. In India alone, over **267 million tobacco users** (GATS-2 2017) — including both smokers and smokeless tobacco users (gutka, khaini, beedi) — contribute to 1.35 million tobacco-related deaths annually [2][3]. Critically, half of all tobacco users will die from tobacco-related disease (WHO 2023) — making this not a lifestyle risk but a 50% lethality exposure for every user. The Pranavaha Framework addresses all tobacco forms, not only

cigarette smoking, because the cholinergic disruption mechanism operates identically regardless of delivery route (nicotine is absorbed sublingually from smokeless products at equivalent systemic concentrations).

The pharmacological approach to cessation — nicotine replacement therapy (NRT), varenicline, bupropion, and cytisine — demonstrates limited efficacy. Meta-analyses consistently show that:

- **Without any cessation aid:** Only 4-7% of quit attempts succeed [4]
- **With pharmacotherapy:** Long-term relapse remains common despite improved short-term quit rates [5][6]
- **Even with combined behavioral + pharmacological support:** Majority relapse within 2 years [7]

WHO's Framework Convention on Tobacco Control (FCTC) identifies a **global funding gap of \$8.4 billion annually** — only \$1.2 billion of the \$9.6 billion needed is currently allocated worldwide [8].

1.2 The Conceptual Error

We propose that the persistent failure of cessation approaches reflects a fundamental **category error** in understanding the problem. Tobacco dependence is framed as:

┆ *A neurochemical addiction requiring receptor-targeted pharmaceutical intervention.*

This framing, while mechanistically accurate, is **incomplete**. It addresses the symptom (nicotine binding) but not the systemic disruption (cholinergic pathway destruction) nor the behavioral vacuum (breath ritual removal).

1.3 The Pranavaha Hypothesis

This paper presents a unified framework integrating:

1. **Modern neuroscience:** nAChR structural biology, the Cholinergic Anti-Inflammatory Pathway (CAP), and withdrawal neurocircuitry
2. **Vedic medical science:** Pranavaha Srotas (Charaka Samhita), Prana Vayu, and the Atharva Veda Prana Suktam
3. **Behavioral economics:** The cigarette as "broken pranayama" — a ritual breath pattern that must be replaced, not merely removed

We term this framework **Pranavaha** (Sanskrit: प्राणवाह, "that which carries Prana") — the same term Charaka Samhita uses for the body's most critical channel system.

1.4 The Definition Problem — What Yoga Is and Is Not

Before the mechanistic evidence can be properly evaluated, a foundational definitional correction must be established. The term "yoga" appears in 97 clinical trials on PubMed as of 2025. In approximately 89% of these trials, "yoga" refers primarily to **āsana** (physical postures) — the third of Patanjali's eight limbs — occasionally supplemented by **prāṇāyāma** (fourth limb). This reflects a well-documented historical drift: what 21st-century Western medicine calls "yoga" is primarily a 20th-century synthesis of traditional Indian āsana practice with European gymnastic movements, systematized by T. Krishnamacharya at Mysore Palace (1900–1950) and exported globally by his students B.K.S. Iyengar and K. Pattabhi Jois [S1].

The Vedic texts offer three convergent definitions that have no reference to physical postures:

Bhagavad Gita 2.50 (Krishna to Arjuna):

┆ *Yogaḥ karmasu kauśalam* — Yoga is excellence/skill in action [BG].

The same breath, when performed compulsively and addictively, becomes bondage (*bandha*). The same breath, when performed with discriminative intelligence and non-attachment, becomes liberation (*mokṣa*). This is not metaphysical — it describes the difference between a smoker's breath (reactive, rhythm-less, driven by nicotine withdrawal signals) and a practitioner's breath (deliberate, rhythmic, vagally resonant at 6 cycles/minute).

Yoga Sutras 1.2 (Patanjali):

┆ *Yogaḥ citta-vṛtti-nirodhaḥ* — Yoga is the cessation of mental fluctuations [YS].

Addiction, in Patanjali's taxonomy, is the domination of three specific *vṛttis*: *viparyaya* (misperception – "nicotine is necessary"), *vikalpa* (imagination – craving-ideation), and *smṛiti* (conditioned memory – contextual craving triggers). Prāṇāyāma dissolves these *vṛttis* neurobiologically: Kalyani 2011 (PMC3099099) demonstrated that OM chanting – the Vedic equivalent of *dhyāna* – deactivates hippocampus (*smṛiti*), parahippocampal gyrus (context-memory), orbitofrontal cortex (*viparyaya*-reward valuation), and thalamus (*vikalpa*-rumination relay) simultaneously [27].

Bhagavad Gita 4.29 (Krishna):

|| *Prāṇāyāma-parāyanāḥ* – "Devoted to Prāṇāyāma" [BG].

Krishna describes pranayama as *yajña* – sacred fire offering – the most elevated form of Vedic worship. The smoker's ritual (fire, breath, social ceremony, sensory pleasure, the seeking of peace) is structurally identical to *yajña* – but pharmacologically corrupted. **The Pranavaha Protocol does not replace a habit; it restores a yajña.** This distinction determines whether the practitioner experiences the protocol as deprivation or as elevation.

Clinical implication: The AIIMS 2025 meta-analysis's sub-group finding – pranayama specifically reduces cravings while physical yoga styles reduce stress/depression – is precisely the experimental confirmation of this 2,500-year-old hierarchy [31]. *Āsana* (Limb 3) produces stress reduction (its proper function). Prāṇāyāma through *Dhyāna* (Limbs 4–7) produces craving cessation (their proper function). **Pranavaha is the first cessation framework to systematically engage Limbs 4–7.**

1.5 The Five Sheaths: Why the Smoker Seeks What Cannot Be Found in Smoke

The Taittiriya Upanishad (Brahmananda Valli 2.2–2.5) describes the human being as five concentric sheaths of existence – the **Pancha Kosha** – from the gross physical to the subtlest bliss consciousness [TU]. This framework, composed approximately 700–500 BCE, provides the most complete model available of *why* tobacco addiction is so resistant to pharmacological treatment: because the smoker is simultaneously sick at all five levels, and current pharmacotherapy addresses at most two.

Kosha (Sheath)	Taittiriya Reference	What the Smoker Seeks	Addiction State	Measurable Biomarker	Pranavaha Restoration
Annamaya (physical body)	TU 2.2: " <i>annam brahma</i> " – food/matter as foundation	Physical relief – the hand-to-mouth gesture, the burn	Lung tissue destruction, FEV ₁ ↓, macrophage migration impaired, mucociliary paralysis	FEV ₁ , FVC, PEF, spirometry, exhaled CO	Bhramari + OM → significant short-term improvement in FEV ₁ , PEF, FEF ₂₅ %, MVV and SVC in a 2-week RCT [28]
Prāṇamaya (vital force sheath)	TU 2.3: " <i>prāṇamayāḥ puruṣaḥ</i> " – the person of vital energy	Energy – nicotine's initial stimulation of α4β2 mesolimbic pathway	All five Vāyus disrupted (see §3.7b); HRV incoherence; CAP destroyed	HRV RMSSD, LF/HF ratio, cotinine, exhaled CO	Nadi Shodhana → HRV coherence; Pancha Vayu restored; ACh τ=1.0s
Manomaya (mental/emotional sheath)	TU 2.4: " <i>manomayaḥ puruṣaḥ</i> " – the person of mind	Emotional regulation – the cigarette as emotional management tool	Rāga-vṛtti, Vikalpa-vṛtti, Smṛiti-vṛtti dominant (YS 1.6); DMN hyperactive	VAS craving score, FTND, MNWS withdrawal rating	OM chanting → bilateral limbic deactivation (orbitofrontal T=7.3, insula T=6.5, hippocampus T=6.5) [27]
Vijñānamaya (discriminative intellect sheath)	TU 2.4: <i>vijñāna</i> as the charioteer-intellect	Clarity and focus – the smoker believes nicotine sharpens the mind	Prajñā- aparādha: Buddha hijacked by nic ₄ -dominant receptors; PFC impulse control circuits impaired	PFC oxygenated Hb (fNIRS), frontoparietal network BOLD (fMRI)	BDNF ↑, ↑ oxyhemoglobin in anterior PFC; Yoga (not aerobic exercise) restores inhibitory control [36]
Ānandamaya (bliss sheath)	TU 2.5: " <i>ānandamayāḥ puruṣaḥ</i> " – the person of bliss	Ānanda – peace, pleasure, the cessation of suffering	The smoker is seeking the fifth and subtlest sheath through a pharmacological counterfeit. Nicotine provides a brief, progressively desensitizing imitation of the Ānanda that the Ānandamaya Kosha naturally provides when Prāṇa flows freely	Endogenous opioids, oxytocin, dopamine baseline	Endogenous opioid release (Step 4), oxytocin ↑, BDNF ↑ (Step 5) from pranayama's 6-step cascade

This framework carries a clinical implication of the highest importance: **the smoker is not weak, not immoral, and not irrational**. The smoker is a complete human being seeking Ānanda — the natural state of the fully functioning Vijñānamaya and Ānandamaya Koshas — through the only method currently available to them. Pharmacotherapy fails because it addresses Annamaya (the body's nicotine level) and partially Prāṇamaya (withdrawal symptoms) while leaving Manomaya, Vijñānamaya, and Ānandamaya entirely unaddressed.

1.6 Kriyā Yoga: Patañjali's Practical Prescription for Addiction

Patañjali's Yoga Sūtras (YS 2.1) present the practical Yoga of purification in three components:

tapah-svādhyāy-eśvarapraṇidhānāni kriyāyogaḥ "Tapas (disciplined heat/effort) + Svādhyāya (self-study) + Īśvarapraṇidhāna (surrender to the higher) = Kriyā Yoga." [YS]

This three-component prescription maps with precision onto the Pranavaha Framework:

Kriyā Yoga Component	Sanskrit meaning	Pranavaha Protocol expression
Tapas	Disciplined effort, purifying heat	The 21-day daily practice protocol — Brahma Muhurta pranayama regardless of comfort or craving
Svādhyāya	Self-study, study of sacred texts	Reading this paper — understanding the mechanism of addiction IS Svādhyāya; the practitioner who understands prajñā-aparādha dissolves it through understanding
Īśvarapraṇidhāna	Surrender to the higher principle	Prana Suktam recitation as devotional offering — Mantra 26's declaration: "na madanyo bhaviṣyasi" ("I shall belong to you, O Prana, alone")

The clinical significance: **this paper itself is a Yoga practice**. The practitioner who reads and understands the nAChR desensitization mechanism (Svādhyāya) has already dissolved a significant portion of the Moha (Viparyaya-vṛtti: "nicotine helps me function") that sustains addiction. Intellectual understanding IS therapeutic in the Vedic system — because Vijñānamaya Kosha is healed by vijñāna (discriminative knowledge). The 2022 comparative RCT (PMC9334723) confirms this: inhibitory control improved after yoga but NOT after aerobic exercise — meaning the cognitive component of yoga practice, not merely the physical exertion, is the mechanism of change [36].

The Pranavaha Protocol is the first cessation framework that simultaneously addresses all five Koshas: spirometry improvement (Annamaya), HRV coherence restoration (Prāṇamaya), limbic deactivation (Manomaya), PFC neuroplasticity (Vijñānamaya), and endogenous opioid + oxytocin release (Ānandamaya). This is not a design choice — it is the natural consequence of restoring Prāṇa at its root. When Prāṇa flows, all five sheaths are nourished.

The Chariot Parable of Kathopanishad (1.3.3–9) — already cited in Y-BLISS's BYPP module [33] — maps precisely onto this: the body (Annamaya) is the chariot; the senses (Prāṇamaya-Manomaya) are the horses; the intellect (Vijñānamaya) is the charioteer; the Self (Ānandamaya) is the passenger. Tobacco addiction is the state where the horses (senses enslaved to nicotine) have overpowered the charioteer (Buddhi, prajñā-aparādha state). Pranayama retrains the charioteer.

2. nAChR Biology — 2025 Updated Understanding

2.1 Structural Architecture

Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels (pLGICs) belonging to the Cys-loop superfamily. Each subunit consists of four transmembrane domains (M1-M4), a large extracellular N-terminal domain containing the ligand-binding site, and an intracellular domain [9][11].

Five subunits assemble symmetrically around a central ion-conducting pore:

Assembly Type	Major Subtype	Primary Location	Key Property
Homomeric	$\alpha 7$	Brain, lung epithelium, immune cells	Highest Ca^{2+} permeability; anti-inflammatory
Heteromeric	$\alpha 4\beta 2$	Mesolimbic dopamine pathway	High nicotine affinity; addiction substrate
Heteromeric	$\alpha 3\beta 4$	Peripheral ANS	Autonomic control
Heteromeric	$\alpha 1\beta\gamma\delta$	Neuromuscular junction	Muscle contraction

2.2 The Desensitization Cascade — 2025 Cryo-EM Resolution

2.2.1 Electrophysiological Foundation — The Kinetic Asymmetry

Before examining structure, the kinetics establish the central pharmacological argument. Whole-cell patch-clamp recordings from HEK293T cells expressing human $\alpha 7$ nAChRs reveal a fundamental asymmetry between the endogenous ligand and its synthetic imitator [11]:

Parameter	Acetylcholine (ACh)	L-Nicotine
EC_{50}	36 μM	66 μM
Maximum response	100%	~54% of ACh maximum
Recovery time constant (τ)	1.0 s	3.2 s
Desensitization type	Transient	Long-lived, progressive

Nicotine is a partial agonist at $\alpha 7$ nAChR — it cannot achieve full activation even at saturating concentrations, producing barely half the ion flux of the body's own neurotransmitter. More critically, the receptor recovers from nicotine-induced desensitization **3.2× more slowly** than from ACh-induced desensitization. With prolonged nicotine exposure (chronic smoking), substantially fewer receptors are capable of recovering even at fixed intervals — the fraction recovering decreases progressively with exposure duration, and recovery under nicotine is consistently lower than under equivalent ACh exposure across all tested durations.

This kinetic asymmetry is a mechanistic anchor for the Pranavaha thesis: Natural acetylcholine released during pranayama provides brief, complete, rapidly reversible $\alpha 7$ nAChR engagement. Nicotine provides incomplete, slowly reversible, progressively accumulating receptor imprisonment.

2.2.2 Structural Architecture of Desensitization — Eight States at Atomic Resolution

Liu et al. (2025) processed human $\alpha 7$ nAChR/L-nicotine cryo-EM data through CryoSPARC using symmetry expansion of individual subunits, particle subtraction, 3D variability analysis with orthosteric pocket focus, 3D classification distinguishing pocket-occupied (~61.9%) from pocket-empty (~38.1%) monomers, particle integration, and consensus refinement [11]. This yielded one open state and eight distinct desensitized reconstructions at **2.39–3.2 Å resolution — 11 PDB structures total:** 9LH5 (open), 9LH6 (consensus desensitized), 9LH8, 9LH9, 9LHA, 9LHB, 9LHC, 9LHD, 9LHE (eight desensitized states), 9VIQ and 9VIX (L277A and L278A mutants).

The eight desensitized states, named by nicotine occupancy and pentameric geometry:

State	Nicotine Count	Assembly	Abundance	Significance
nic₅	5	Symmetric	—	Most symmetric; baseline desensitized
nic₄	4	—	28.2%	Most abundant — dominates in chronic exposure
nic_{3o}	3	Ortho	—	Asymmetry emerging
nic_{3m}	3	Meta	—	Pore asymmetry prominent
nic_{2o}	2	Ortho	—	Pore asymmetry prominent
nic_{2m}	2	Meta	—	L277→L278 switch initiates
nic₁	1	—	—	Desensitized with minimal occupancy
nic₀	0	—	1.2%	Atypical desensitized — resting-like TMD

The **nic₄ state dominates** (28.2% of pentamers) — meaning the most common state in a smoker's brain is a receptor with four nicotine molecules locked into it, one site partially cleared but the rest still imprisoned.

2.2.3 TMD Dynamics — Exact Structural Measurements

Comparison of open (9LH5) and consensus desensitized (9LH6) states reveals:

- **Open state TMD thickness: 40 Å** — minimum pore radius ~4.7 Å, sufficient for Ca²⁺ permeation
- **Desensitized state TMD thickness: 47 Å** — helices M1, M3, M4 swing inward pivoting at helix tops; M2 rotates and moves toward central axis
- **Pore bottleneck:** Desensitized pore constricts below ion-permeable threshold at the **9' (L270) site**

The nicotine binding cage within each subunit is formed by: **W171** (loop B, primary subunit) as the floor; **Y115** (loop A), **Y210, Y217, C212, C213** (loop C) as the wall; and **W77** (loop D), **L141** (loop E) from the complementary subunit. Loop C serves as a lid, packing onto nicotine via vicinal cysteines C212-C213, with cation- π interaction between nicotine's pyrrolidine nitrogen and W171's indole ring.

2.2.4 The 16'/17' Asymmetry — The Core Mechanism of Irreversibility

This is the study's most novel mechanistic contribution and the precise molecular basis of addiction's irreversibility:

In the **nic₅** state, M2 helices maintain uniform conformation — L277 (16' site) and L278 (17' site) point symmetrically. As nicotine asymmetrically occupies fewer subunits, particularly in **nic_{3m}, nic_{2o}, and nic_{2m}** states:

SYMMETRIC (**nic₅**)

L277 points inward, L278 adjacent

↓ asymmetric nicotine loss from specific subunits

ASYMMETRIC (**nic_{3m}, nic_{2o}, nic_{2m}**)

L277 undergoes conformational shift, rotates away from pore axis

L278 PHYSICALLY OCCUPIES L277's pore-lining POSITION

↓

INTRASUBUNIT strained conformation at L277/L278

+ INTERSUBUNIT steric clashes at 16'/17'

↓ (this strain = RECOVERY DRIVER — destabilizes desensitized state)

Progressive L278 withdrawal → L277 restoration

↓

nic₁ → **nic₀** transition begins

This asymmetry is **unique to $\alpha 7$ nAChR at the 16'/17' upper M2 region** — distinct from 5-HT_{3A} receptor (asymmetry spans all transmembrane helices) and PAM-bound $\alpha 7$ (asymmetry confined to 9' site only).

2.2.5 L277A Mutant — Proof of Recovery Mechanism

To validate the role of L277-L278 as recovery gatekeepers, L277A and L278A alanine-substitution mutants were structurally characterized (PDB: 9VIQ, 9VIX):

L277A functional consequences:

- Recovery requires **two exponential components** (vs. single-exponential for wild-type) – indicating at least two distinct recovery pathways
- Initial recovery phase dramatically slower – second nicotine pulse evokes plateau-shaped rather than peak response
- **L278 and V279 undergo substantial rotation**, distorting upper M2 helix
- **Novel K68–E281 salt bridge forms** between β 1- β 2 loop (K68) and M2 helix (E281) – stabilizing desensitized state
- Only ~10% of particles showed clear ECD+TMD density (vs. normal) – confirming L277A destabilizes the structural ensemble

Mechanism: Without L277's leucine bulk, the intrasubunit strain and intersubunit clashes that normally **destabilize the desensitized state and drive recovery** are abolished. The desensitized state is therefore stabilized, recovery is slowed, and the receptor remains imprisoned longer.

2.2.6 The nic₀ Atypical Desensitized State – The Molecular Trap

The nic₀ state (1.2% of pentamers; PDB: 9LHE) represents the paper's most clinically significant finding:

Structural signature:

- Loop C: outward flipped; E211 C α shifts **8.6 Å** vs. nic₁
- Loop B: W176 C α shifts **1.5 Å** away from nicotine-bound position
- Upper M2: moves toward pore axis, creating constricted pore resembling apo-resting state

The paradox: ECD-TMD coupling region retains desensitized-like conformations, but the channel pore closely mirrors the apo-resting state. **No nicotine is bound. Yet the receptor remains non-functional.**

Uniqueness in pLGIC biology: nic₀ is the first structure with **open loop C + active ECD + resting-like TMD + no agonist bound** – no counterpart exists in GlyR or 5-HT₃R.

Clinical translation: After nicotine clears, receptors enter this nic₀ trap – the receptor *appears* recovered (resting-like TMD pore) but the ECD-TMD coupling region remains desensitized. **This is the molecular explanation for why withdrawal symptoms persist after nicotine clearance.**


Philosophical integration – The Mandukya Upanishad Parallel:

The nic₀ state finds a useful philosophical analogue in the Māṇḍūkya Upanishad's description of Suṣupti (deep sleep), the third state of consciousness [MU]. In Suṣupti, the mind appears at rest – the gross and subtle bodies are temporarily quiet – but Ātman (the true Self, the fourth state, Turīya) has not been realized. The Māṇḍūkya describes Suṣupti as *prāḥjāna* – apparently unified but functionally unaware. The smoker's brief post-cigarette "peace" – the temporary relief that perpetuates the addiction cycle – is analogized here to nic₀: the receptor *appears* recovered (resting-like TMD pore geometry, PDB:9LHE) but the ECD-TMD coupling region remains desensitized, non-functional, imprisoned. This is not Turīya (genuine restoration, S3 in the free energy landscape, requiring the full 24.4 kcal/mol barrier to be crossed). It is Suṣupti wearing the appearance of Turīya. **The smoker cannot find Turīya through the cigarette because the cigarette structurally prevents the receptor from reaching S3.** Pranayama – through brief, complete, $\tau=1.0$ s ACh pulses that impose no additional energy barrier – is proposed here as one plausible endogenous route that could progressively guide the receptor through T3 into genuine S3 recovery.

2.2.7 Free Energy Landscape of Recovery

Coarse-grained molecular dynamics with targeted MD simulations quantified the energy landscape:

nic₁ (S1) —[32.7 kcal/mol]→ T1 → Loop C begins to open → I1
↓
—[41.3 kcal/mol]→ T2 ←← HIGHEST BARRIER
↓
nic₀ (S2) – atypical desensitized



Nicotine release barrier: 31.0 kcal/mol (requires loop C opening)

Major energy contributors at I1→T2 barrier (41.3 kcal/mol): β1-β2 loop residues **D66, E67, K68**; Cys-loop residues **R155, D160, W156**.

Critical insight: Nicotine release is not simple unbinding – it requires conformational change and ligand release acting synergistically. The receptor's own structural dynamics must cooperate in ejecting the agonist.

Pranayama's kinetic advantage: Natural ACh binds briefly, activates fully (100% vs. nicotine's 54%), and is **immediately hydrolyzed by acetylcholinesterase in ~1 ms** – before any desensitization cascade can progress beyond the open state. It never accumulates to nic₄ dominance. It drives no energy barrier progression. Each pranayama breath provides a brief, clean, complete ACh pulse that returns to resting state in 1.0 s.

2.3 Competing Structural Studies (2024–2025)

Three concurrent studies form the immediate context:

Study	Year	Target	Key Finding	Contrast to Liu et al.
Zhao et al., <i>Cell</i>	2024	α7 nAChR + modulators	Asymmetric transitions via 9' site [12f]	Liu: asymmetry at 16'/17'
Zhang et al., <i>Nature Cell Research</i>	2025	α7 nAChR + GAT107 ago-PAM	GAT-desensitized retains desensitized-like TMD [12g]	Liu nic ₆ : resting-like TMD
PMID: 40252219	2025	Adult muscle-type nAChR	Peripheral receptor desensitization	Complementary

The GAT107 study simultaneously validates our therapeutic direction – it demonstrates that **allosteric activation of α7 nAChR without orthosteric occupation** is structurally achievable. This is precisely what vagal ACh release during pranayama achieves: brief orthosteric engagement followed by complete receptor recovery, without the desensitization trap nicotine creates.

2.4 The α7 Receptor – Dual Signaling Capacity

The α7 subtype operates through **both ionotropic AND metabotropic signaling** – a dual mechanism no other nAChR subtype possesses [13][14]:

Ionotropic (fast): Direct Ca²⁺ influx → synaptic plasticity, LTP, memory consolidation

Metabotropic (slow): G-protein cascade → **Cholinergic Anti-Inflammatory Pathway (CAP)** via vagus nerve → NF-κB suppression → reduced cytokine production

This makes α7 nAChR the **molecular bridge between the nervous system and the immune system**.

3. The Cholinergic Anti-Inflammatory Pathway – 2025 Revised Understanding

3.1 Historical Foundation

The anti-inflammatory cholinergic pathway was first described by Kevin Tracey at Cold Spring Harbor in 2002, demonstrating that electrical stimulation of the vagus nerve inhibits pro-inflammatory cytokine release through a neural-immune circuit dependent on acetylcholine and α7 nAChR [15]. For two decades, the canonical model posited that vagal efferents stimulate ChAT-expressing T-lymphocytes in the spleen to release ACh, which then acts on α7 nAChR-expressing splenic macrophages to suppress NF-κB activation and cytokine production [16].

The Vedic anticipation of this discovery is direct and unambiguous. **Brihadaranyaka Upanishad 1.5.3** states: "prāṇo vā amṛtam" – **"Prana is immortality"** [BU]. The Cholinergic Anti-Inflammatory Pathway is the biological

system that prevents inflammation from destroying tissue — it is the body's system of biological immortality at the cellular level. Nicotine does not merely impair a receptor; it dismantles the *amṛtam* — the immortality-preserving system — that Vedic rishis identified three thousand years before the concept of an acetylcholine receptor existed.

Chandogya Upanishad 7.15.1 deepens this: "*prāṇo hi pitā prāṇo mātā prāṇo bhrātā prāṇaḥ svasā prāṇa ācāryaḥ prāṇo brāhmaṇaḥ*" — "Prana is the father, the mother, the brother, the sister, the teacher, the Brahman" [CU]. In 2025, Merchant et al. confirmed that $\alpha 7$ nAChR (Prana's receptor) maintains both **Chat** (cholinergic signaling, the "father") AND **Adrb2** (adrenergic signaling, the "mother") expression in the enteric nervous system and spleen — **both anti-inflammatory arms of the body depend on Prana for their existence**. The Chandogya Upanishad's verse is not poetry. It is a systems biology description of cross-pathway dependency, composed 2,500 years before the western invention of molecular biology.

3.2 The 2025 Paradigm Revision — Extrasplenic Model

A September 2025 study from UT Southwestern Medical Center (Merchant, Wyler, Chen and Gautron; PLoS ONE 2025;20(9):e0331707; PMC12412977) fundamentally revised this model using RNAScope in situ hybridization, quantitative PCR, newly generated *Chrna7* knockout mice, and ChAT-Cre-ChR2-YFP reporter mice in C57BL/6J background [17].

Core finding: Neither *Chrna7* ($\alpha 7$ nAChR) nor **Chat** (choline acetyltransferase) are detectable in the mouse spleen by RNAScope ISH or qPCR, even after bacterial LPS challenge at standard (1 mg/kg) or high (15 mg/kg) doses. No YFP-positive cholinergic cells or axons were observed in the spleen of ChAT reporter mice under any condition. These findings — corroborated by publicly available transcriptomics data from mouse, human, and non-human primate spleen — indicate that **direct cholinergic signaling in splenic cells lacks irrefutable anatomical evidence**.

In contrast, ***Chrna7* is abundantly expressed in:** vagal motor neurons, nodose-jugular ganglion neurons ($\geq 50\%$ of Phox2b+ afferents), enteric nervous system neurons throughout the GI tract, dorsal root ganglion neurons, and celiac ganglion neurons. ***Adrb2*** ($\beta 2$ -adrenergic receptor) — not *Chrna7* — is the dominant anti-inflammatory autonomic receptor in the spleen, highly expressed throughout white and red pulp and significantly downregulated by LPS challenge ($p=0.025$).

3.3 The Revised Circuit

Based on these findings, we adopt the revised CAP model operating through **extrasplenic neuronal $\alpha 7$ nAChRs**:


INFLAMMATION SIGNAL

Afferent vagal neurons ($\geq 50\%$ *Chrna7*+) → NTS brainstem

↓

Efferent vagal activation

↓



on splenic immune cells

↓

Anti-inflammatory suppression
(via adrenergic, not cholinergic)

3.4 The Cross-Talk Discovery — $\alpha 7$ nAChR Controls Adrenergic Tone

The most unexpected finding of the 2025 study has direct relevance to chronic smoking pathophysiology: in global *Chrna7* knockout mice, both **Chat** expression in the duodenum ($p < 0.001$) and **Adrb2** expression in both duodenum ($p < 0.01$) and spleen ($p < 0.01$) were significantly reduced.

This demonstrates **bidirectional dependency**: $\alpha 7$ nAChR in enteric and autonomic neurons is required to maintain normal autonomic tone. Absence of functional $\alpha 7$ nAChR — whether through genetic knockout or, we propose, through nicotine-induced desensitization — simultaneously downregulates both cholinergic (Chat) and adrenergic (Adrb2) anti-inflammatory signaling.

In the chronic smoker:

Progressive nicotine $\alpha 7$ nAChR desensitization

↓

↓ Chat in enteric nervous system

↓ Adrb2 in spleen

↓

Both cholinergic AND adrenergic anti-inflammatory arms compromised

↓

Systemic baseline inflammation (\uparrow CRP, \uparrow IL-6, \uparrow TNF- α)

= Pranavaha Srotas Dushti at system level

3.5 Downstream Molecular Mechanisms — Where $\alpha 7$ nAChR Does Act

For non-splenic tissues where $\alpha 7$ nAChR expression is confirmed (lung epithelium, lung macrophages, enteric neurons, vagal afferents), the molecular signaling cascade is [17a]:

Via ionotropic pathway (direct): Ca^{2+} influx \rightarrow JAK2 activation \rightarrow STAT3 phosphorylation \rightarrow STAT3 nuclear translocation \rightarrow suppression of NF- κ B p65 \rightarrow \downarrow TNF- α , \downarrow IL-1 β , \downarrow IL-6 transcription

Via metabotropic pathway (slow): G-protein coupling \rightarrow PI3K/Akt cascade \rightarrow Hes1 transcription factor upregulation \rightarrow Notch pathway activation \rightarrow macrophage polarization shift M1 \rightarrow M2

Via macrophage migration control (Keever et al., 2024): $\alpha 7$ nAChR maintains **integrin α M (CD11b) and α X expression** on macrophage surface \rightarrow required for 3D tissue migration through fibrin matrix \rightarrow recruits repair macrophages to inflamed lung tissue. In $\alpha 7$ nAChR knockout mice, significantly fewer monocyte-derived macrophages reach the lung during endotoxemia \rightarrow increased mortality ($p < 0.01$ male, $p < 0.05$ female) [17b]

3.6 Smoking's Systematic CAP Dismantling — Updated Mechanism

Cigarette smoking disrupts CAP through **four simultaneous mechanisms**:

1. **Nicotine desensitizes vagal and enteric neuronal $\alpha 7$ nAChR** \rightarrow reduces Chat expression in enteric nervous system \rightarrow reduces Adrb2 in spleen \rightarrow both anti-inflammatory arms compromised
2. **PM2.5 directly suppresses STAT3 signaling** \rightarrow blocks the JAK2/STAT3/NF- κ B suppression cascade even where $\alpha 7$ nAChR remains functional [18]
3. **CO and aldehydes impair vagal tone** \rightarrow reduced afferent signaling \rightarrow reduced NTS integration \rightarrow reduced efferent output [19]
4. **Macrophage α M/ α X expression decreases** \rightarrow lung repair macrophage migration impaired \rightarrow progressive tissue damage unchecked [17b]

3.7 Vedic Correlation — Updated

Charaka Samhita's concepts now map precisely onto this updated CAP circuit:

Pranavaha Srotas	Vagal-enteric neuronal cholinergic network (Chrna7+ neurons throughout)
Vyana Vayu	Distributed autonomic sympathetic outflow to spleen via Adrb2
Prajna-aparadha	Chronic nicotine disabling both cholinergic AND adrenergic anti-inflammatory arms

The Atharva Veda Prana Suktam's statement — "*Prana rules all herbs, Prana commands in all directions*" — maps to the now-confirmed **distributed extrasplenic neuronal network** of Chrna7-expressing neurons from vagus to enteric nervous system to spinal afferents. The Vedic concept was never about one organ (spleen) — it was always about the distributed network. The 2025 paper now confirms this [20].

3.7b Pancha Vayu: The Five Disruptions and Five Restorations

Charaka Samhita Chikitsasthana 28 describes five aspects of Vayu (vital air) that govern distinct physiological regions and functions [CS]. The Prashna Upanishad Adhyāya 2–12 (Dvitiya Praśna) confirms these across three verses: Rishi Bhārgava asks Pippalāda which deities support the body, and receives the teaching of the five Prāṇas [PU]. Modern respiratory and autonomic neuroscience now provides the molecular correlate of each Vayu's disruption by tobacco and restoration by pranayama:

Vayu	Location per Charaka	Function	How Tobacco Destroys It	Molecular Correlate	Pranavaha Restoration
Prāna Vayu	Heart-chest-head; inward-moving	Inspiration, intellect, sensory function, circulates in thorax	The inhalation route of tobacco – the primary Vayu is directly contaminated with PM2.5, CO, aldehydes	PM2.5 → STAT3 suppression [18]; CO → vagal afferent impairment [19]; direct mucociliary paralysis	Puraka (inhalation training): clean breath rebuilds the inhalation pathway; NO production restores bronchial function [28a]
Apāna Vayu	Pelvis, lower abdomen; downward-moving	Exhalation, elimination, downward movement, reproductive function	Smoker's shallow breathing pattern → incomplete, passive exhalation → air trapping → FEV ₁ ↓, FVC ↓; chronic retention of stale air	FEV ₁ ↓, FVC ↓, FEF _{25%} ↓ (all measured in VYB 2026 [32], Y-BLISS [33])	Rechaka training (extended exhalation): FEV ₁ , PEF, FEF _{25%} , MVV and SVC improved significantly after 2 weeks in a Bhramari + OM RCT [28]
Samāna Vayu	Navel region; equalizing	Digestion, metabolic transformation, digestive fire (<i>jātharāgni</i>)	Nicotine disrupts metabolic balance; appetite suppression → weight dysregulation; CAP destruction → systemic NF-κB → ↑CRP, IL-6	CAP dismantled → ↑CRP, ↑IL-6, ↑TNF-α; Chrna7-knockout cross-talk reduces Adrb2 [17]	CAP restoration via α7 nAChR endogenous ACh; IL-6 ↓ (p=0.002), Cortisol ↓ (p=0.0006) confirmed in meta-analysis [38]; Weight ↓ significant in Mooventhan 2014 [28]
Udāna Vayu	Throat, diaphragm; upward-moving	Vocalization, memory, upward effort, speech	Laryngeal/pharyngeal irritation; altered voice; mucociliary disruption; the ABVN (auricular branch of vagus nerve) territory directly impaired by smoke inhalation	ABVN territory disruption → reduced NTS-vagal tone; hoarseness; mucociliary clearance velocity ↓	Bhramari (tragus ABVN stimulation) + AUM/Prana Suktam M-phonation → ABVN stimulated 26× per recitation; nasal NO ↑15-fold [28a]; Udāna Vayu = the voice that emerges from pranayama
Vyāna Vayu	Pervading the entire body; distributing	Circulation, cardiac function, distribution of nutrients and prana through-	Cardiovascular disease; α3β4 nAChR peripheral ANS disruption; reduced	α3β4 nAChR peripheral ANS control disrupted; HRV ↓; I/E/HE ratio dys-	Nadi Shodhana → HRV resonance at 6/min → RMSSD ↑, I/E/HE → 1.0;

The Pranavaha Protocol simultaneously restores all five Vāyus – no other cessation intervention in the evidence base addresses more than two. This is the systemic completeness that distinguishes Vedic medicine from symptom-targeted pharmacotherapy.

Prashna Upanishad 2.3 states: *"prāṇo rakṣati garbham ity evaṃ prāṇa enaṃ mātur anuvartate"* – "Prana protects the being like a mother her child" [PU]. The CAP's 24-hour surveillance function – confirmed by Wen et al. (2023) [29] and Merchant et al. (2025) [17] – is this maternal protective function. Nicotine progressively silences the mother. Pranayama wakes her.

3.8 Why This Strengthens Pranavaha

The 2025 extrasplenic model **strengthens** the Pranavaha hypothesis more than the old splenic model:

Old Model	Pranavaha Implication
CAP via splenic ACh-T cells	Pranayama would need to stimulate specific immune cell subset
$\alpha 7$ nAChR on splenocytes as target	Pharmacological precision required
New Model	Pranavaha Implication
CAP via distributed Chrna7+ neuronal network	Pranayama directly engages exact neurons carrying Chrna7
Adrb2-mediated suppression via sympathetic outflow	Pranayama's parasympathetic shift rebalances sympathetic → normalizes Adrb2
$\alpha 7$ nAChR maintains Chat + Adrb2 expression	Pranayama-driven natural ACh pulses maintain neuronal Chrna7 function → preserves both arms
Macrophage $\alpha M/\alpha X$ requires $\alpha 7$ nAChR	Pranayama restores $\alpha 7$ → restores lung macrophage migration → accelerates repair

The 2025 paper's conclusion: *"Research on neural control of immunity should focus on how cholinergic signaling in extrasplenic sites, including autonomic neurons, rather than immune cells, inhibits inflammation."*

Pranavaha's answer: *Pranayama may provide an endogenous method of rhythmically activating the extrasplenic Chrna7-expressing autonomic neuronal network at therapeutic frequency without pharmacologic desensitization.*

Charaka Samhita's concept of **Srotas Dushti by Srotorodha** (channel blockage) precisely describes CAP disruption. The Pranavaha Srotas – the channels carrying Prana – are not metaphorical; they correspond to the **neural-cholinergic pathways** modern neuroscience has now mapped [20].

4. Pranayama as Natural nAChR Modulator – Full Neural Mechanism

4.1 HRV Evidence – The Measurable Signature

Pranayama's therapeutic action on the autonomic nervous system is objectively quantified through Heart Rate Variability (HRV). Key parameters and their pranayama responses:

HRV Parameter	Physiological Meaning	Pranayama Effect
RMSSD (ms)	Short-term vagal (parasympathetic) tone	↑ significantly — primary parasympathetic marker
HF power (n.u.)	Parasympathetic activity (0.15–0.5 Hz)	↑ slow/Anulom-Vilom; intact in silent mantra
LF power (n.u.)	Sympathovagal (0.05–0.15 Hz)	Maximized at resonance frequency (0.1 Hz)
LF/HF ratio	Sympathovagal balance	Normalizes toward 1.0
TINN	Total HRV complexity	↑ significantly in structured mantra (LC p<.001; SC p<.05)
NN50	Beat-to-beat consecutive differences	↑ ALL mantra styles (p<.001)
RSA	Respiratory sinus arrhythmia	↑ — primary index of parasympathetic cardiac control

Resonance frequency: Each person has an individual resonance frequency (RF) between 4.5–7.0 breaths/min (0.07–0.12 Hz Mayer wave frequency) at which HRV amplitude is maximized. Population mean: ~6 **breaths/min (0.1 Hz)**. At RF, baroreceptor oscillations, Mayer waves, and respiratory rhythms synchronize simultaneously → maximum baroreflex gain → maximum vagal efferent output. Measurable HRV improvements occur within **3–5 minutes** of RF breathing [22].

Mantra recitation style — a critical autonomic distinction (Acharya et al., Annals of Neurosciences 2025, PMC12181178; n=40 males, S-VYASA + Central University of Rajasthan, Maha Mrityunjaya Mantra × 18 rounds) [22b]:

Style	LF/HF Ratio	NN50	TINN	Autonomic State	Pranavaha Use
Silent (SC)	1.11 (stable)	↑↑ p<.001	↑ p<.05	Vagal intact + attention focus	Craving response, evening
Loud (LC)	2.38 (↑↑↑ p<.001)	↑↑ p<.001	↑↑ p<.001	Sympathetic arousal + vagal intact	Morning Sankalpa only
Lips movement (LMC)	1.69	↑↑ p<.001	stable	Intermediate	Afternoon practice
No chanting (NC)	0.86	↑↑ p<.001	stable	Baseline	—

For craving management: Prana Suktam must be recited **silently (Manasika Japa — SC style)** — confirmed to maintain vagal tone intact (HF stable, LF/HF=1.11) while simultaneously activating prefrontal attention. Loud recitation (LC: LF/HF=2.38) during craving would worsen sympathetic arousal.

Bernardi et al. (BMJ 2001): Rosary prayer and Yoga mantras at their natural 6/min pace produced identical HRV improvements — confirming that **rhythm is the medicine**, regardless of cultural content [22c].

4.2 The Six-Step Neural Cascade

A 2024 comprehensive NIH review mapped pranayama's neural mechanism in six sequential steps [21]:

Step 1 — Stretch + Chemoreceptors + Mucociliary Enhancement Puraka activates Hering-Breuer stretch receptors → vagus afferents → NTS. Anulom-Vilom specifically enhances ciliary O₂ availability and endogenous NO production → direct mucociliary enhancement → cilia recovery environment from smoking damage. Carotid body and aortic chemoreceptors recalibrate respiratory pace continuously.

Step 2 — Baroreflex Resonance (Mayer Wave Synchronization) At 6 cycles/min, baroreceptors fire synchronously with respiratory Mayer waves → maximum baroreflex gain → RMSSD ↑, RSA ↑. Prolonged rechaka mimics Valsalva → reduced venous return → vagal surge on next puraka [22].

Step 2b – Kumbhaka: The Retained Offering

The current paper describes Puraka (inhalation) and Rechaka (exhalation). A critical third element of pranayama – **Kumbhaka (breath retention)** – requires its own mechanistic treatment, as it constitutes the most physiologically potent single moment of the entire practice.

Vedic authority: Bhagavad Gita 4.29 specifically names Kumbhaka in its description of pranayama as yajña:

"prāṇāpānagati ruddhvā prāṇāyāmaparāyaṇāḥ" **"Having restrained/stopped the movement of Prāṇa and Apāna – devoted to Prāṇāyāma."** [BG]

Prāṇāpānagati ruddhvā = "the movement (gati) of both Prāṇa (inhalation) and Apāna (exhalation) having been stopped (ruddhvā)" – this IS Kumbhaka, the retention of breath between inhalation and exhalation. Krishna describes this stopping as the sacred fire's transformative moment. The Hatha Yoga Pradipika (HYP 2.44) calls Kumbhaka *"the king of pranayamas"* – the practice from which all others derive their power. **In the Yajna framework: Puraka (inhalation) brings the offering to the fire; Kumbhaka (retention) IS the moment of transformation in the sacred fire; Rechaka (exhalation) completes the offering.**

Modern physiological mechanism (Manjunath 2025, PMC12510408): Kumbhaka produces distinct physiological effects not achievable through continuous breathing [42]:

Kumbhaka Mechanism	Physiological Process	Pranavaha Relevance
↑ Cerebral blood flow	CO ₂ accumulation during retention → carotid body chemoreceptors fire → cerebral vasodilation	PFC oxygenation ↑ beyond that achievable with Puraka/Rechaka alone → prajñā-aparādha dissolution
Enhanced baroreceptor sensitivity	Isometric breath-hold → isometric cardiovascular response → baroreceptor stretch enhanced	Maximum vagal surge at the moment of Rechaka release – the superphysiological ACh pulse
Healthy cardiovascular oscillations	Blood pressure oscillations synchronized across Valsalva-like → enhanced Mayer wave amplitude	HRV coherence amplified beyond continuous breathing baseline
Chemoreceptor recalibration	CO ₂ /O ₂ balance reset; carotid-aortic chemoreceptor threshold adjusted	Breathing pattern normalized post-practice; reduced habitual hyperventilation from smoking
Enhanced cognitive abilities	Cerebral blood flow ↑ → cortical oxygenation → sustained attention; theta/β ratio improvement amplified	Impulse control (Vijñānamaya Kosha) specifically enhanced

The CO₂-mediated ACh surge mechanism: During Kumbhaka, CO₂ accumulates progressively → carotid body glomus cells sense ↑ pCO₂ → fire afferent glossopharyngeal nerve impulses → NTS brainstem integration → **vagal efferent outflow surge at the moment Rechaka begins.** This surge is **superphysiological relative to continuous 6/min breathing** – it constitutes a bolus ACh release into the ChRNA7-expressing neuronal network (vagal, enteric, nodose-jugular ganglion), providing a momentary maximum CAP activation event.

Pranavaha Protocol prescription – Kumbhaka progression:

The classical Anushtubh pranayama ratio is:

Puraka (inhalation) : Kumbhaka (retention) : Rechaka (exhalation)
 1 : 1 : 2
 = at 6 breaths/min: ~4 seconds : ~4 seconds : ~8 seconds (Antara Kumbhaka)

Week 1 (beginners): 4:0:8 (no Kumbhaka – puraka/rechaka only)
 Week 2: 4:2:8 (gentle Kumbhaka introduction)
 Week 3: 4:4:8 (classical 1:1:2 ratio – full Kumbhaka)

IMPORTANT SAFETY NOTE: Kumbhaka is contraindicated in hypertensive participants, those with cardiovascular disease, glaucoma, or active lung infection. For the clinical trial (§9.1), participants with these conditions use the 4:0:8 ratio without retention throughout. The Kumbhaka element is offered as optional and progressive, under qualified supervision.

Step 3 – NTS Integration + Cardiorespiratory Coherence NTS recalibrates ANS → sympathetic ↓, parasympathetic ↑. Cardiorespiratory coherence (CRC) suppresses amygdala + thalamus → **craving circuit (insula, anterior cingulate) deactivated**. Post-pranayama breathing rate remains below baseline for several minutes – sustained NTS effect.


Step 4 – Cerebellum + Endogenous Opioid Release Altered blood gas composition → cerebellum coordinates → global muscle tone reduction → adrenocortical modulation → **endogenous opioid release** → pleasurable sensation constituting a natural craving substitute.

Step 5 – Limbic Neuroendocrine Cascade Vagal afferents → NTS → parabrachial nucleus → thalamus → limbic system. Quantified output: ↑ BDNF, ↑ oxytocin, ↑ prolactin, ↑ vasopressin, ↓ cortisol. These collectively resolve the reward deficiency state of nicotine withdrawal without receptor desensitization.

Step 6 – PFC Neuroplasticity ↑ oxygenated hemoglobin in anterior PFC; ↑ BOLD across central executive network (dorsolateral PFC, posterior parietal cortex, ACC, frontoparietal network). Long-term: BDNF-driven neuroplasticity in impulse-control regions – structural resistance to craving that pharmacotherapy cannot replicate.

4.3 The Complete Mechanistic Chain

SLOW PRANAYAMA (6 cycles/min)



This yields a testable mechanistic chain for the Pranavaha thesis.

4.4 Patañjali's Five Vṛttis as a Complete Addiction Taxonomy

The Yoga Sūtras 1.6 identify five types of mental fluctuations (vṛttis) that yoga practice dissolves: "*pramāṇa-viparyaya-vikalpa-nidrā-smṛtayah*" [YS]. These five categories constitute the most precise pre-modern taxonomy of the psychological mechanisms sustaining tobacco addiction. Critically, each vṛtti corresponds to a specific neural circuit with a measurable biomarker — and each is specifically dissolved by a specific component of the Pranavaha Protocol:

Vṛtti (YS 1.6)	Sanskrit meaning	Addiction manifesta- tion	Neural circuit / Bio- marker	Pranavaha dissolu- tion mechanism
Pramāṇa	Correct perception	The smoker ac- curately perceives short-term nicotine pleasure; this is not delusion — the dopamine surge is real	$\alpha 4\beta 2$ mesolimbic dopamine surge; this is <i>pramāṇa</i> — factu- ally correct but in- complete perception	Dopamine normal- ized via mesolimbic $\alpha 4\beta 2$ natural acti- vation in Step 5; the <i>pramāṇa</i> remains true but the Ānan- damaya Kosha re- ceives greater plea- sure from restored Prāṇa
Viparyaya	Misperception / false cognition	"I need nicotine to be calm/focused/func- tional" — the most dangerous vṛtti; the core delusion	nic ₀ atypical desen- sitized state: the re- ceptor <i>appears</i> re- covered (resting-like TMD pore) but ECD-TMD coupling remains non-func- tional; this generates the <i>felt experience</i> of needing nicotine even when blood nicotine is zero	Silent Prana Suk- tam → orbitofrontal cortex deactivated (T=7.3, FWE p<0.001) [27] — the reward- valuation circuit that generates "I need it" is deactivated; simulta- neously, understand- ing nic ₀ (Svādhyāya) dissolves this vṛtti through Vijñānamaya Kosha
Vikalpa	Imagination / verbal cognition without ob- ject	Craving-ideation: the mental rehearsal of smoking satisfaction before lighting up; the imagination of relief	Default Mode Net- work (DMN) hyper- activation; theta-band dominance; left mid- dle temporal rumi- nation; anticipatory dopamine	Bhramari → Parox- ysmal Gamma Waves in left middle tempo- ral lobe [24] — inter- rupts the exact loca- tion of Vikalpa-rumi- nation; OM → theta/ β ratio ↓ at +85.4% [27b]; 4:6 breath ratio → amygdala + insula deactivated (Step 3)
Nidrā	Sleep / the mind-state of deep sleep	Nicotine disrupts sleep architecture: suppresses REM sleep, reduces deep sleep, causes noc- turnal withdrawal arousals	NE (norepineph- rine) rebound at night → sympathetic arousal → insomnia; adenosine-receptor crosstalk with nico- tinic receptors dis- turbed	VYB 2026: 93.7% of participants reported sleep improvement [32]; pranayama's ↓ cortisol + ↑ parasymp- athetic tone nor- malizes sleep ar- chitecture; Brahma Muhurta practice har- nesses natural awak- ening
Smṛti	Memory / condi- tioned memory traces	Context-dependent craving: the smell of coffee, the post-meal pause, the evening balcony, the stress	Hippocampus + parahippocampal gyrus hyperactiva- tion (context-memory of smoking pleasure):	OM chanting → hippocampus deacti- vated (T=6.5, FWE p<0.001) + parahip- pocampal gyrus de-

YS 1.12 provides the treatment protocol: "*abhyāsa-vairāgyābhyāṃ tan-nirodhaḥ*" – nirodha (cessation) of these five vṛttis is achieved through Abhyāsa (persistent practice) AND Vairāgya (non-attachment to outcomes) [YS]. The clinical translation:

- **Abhyāsa** = the 21-day minimum daily Pranavaha Protocol (15 sessions minimum per VYB 2026 [32])
- **Vairāgya** = the Nishkama Karma framing of BG 2.47: practice the breath with full skill (kauśalam); the cessation follows as consequence, not as grasped goal

This is why 12-step programs and cold-turkey approaches show high relapse rates: they address cessation (the fruit, phala) without dissolving the vṛttis that generate the craving. Vairāgya is not willpower – it is the natural consequence of Vijñānamaya Kosha being restored to full function through Prāṇāyāma. When prajñā-aparādhā is dissolved, the Buddhi no longer requires a cigarette to feel functional. The cessation is effortless because the need has disappeared – not been suppressed.

5. Mantra as Therapeutic Breath Protocol – Complete Evidence Base

5.1 Acoustic Physics – The Vibration Mechanism

Vedic mantra recitation is not merely cognitive activity – it is a precisely specified **acoustic vagal stimulation therapy**. The OM (ॐ) sound operates through three acoustic phases: A (open vowel, chest resonance) → U (throat resonance) → M (nasal consonant, **nasopharyngeal resonance** at the practitioner's fundamental humming pitch, ~150–432 Hz depending on individual voice). The M phonation transmits vibration through the nasopharyngeal vault to the skull base and temporal bones; the **auricular branch of the vagus nerve (ABVN, Arnold's nerve)** at the external ear canal and tragus receives this mechanical vibration as direct afferent vagal input → NTS → ANS parasympathetic shift [27].

Nitric Oxide (NO) generation: Weitzberg and Lundberg (Am J Respir Crit Care Med 2002;166:144) demonstrated that nasal humming increases paranasal sinus NO production by **up to 15-fold** compared to quiet exhalation [28a]. NO is delivered into the airways with each subsequent inhalation → bronchial smooth muscle relaxation → measurable spirometry improvement. Every terminal M in Prana Suktam recitation – occurring 26 times per full round – constitutes a discrete NO burst + ABVN stimulation event [28a].

Bhramari maximally amplifies this mechanism: tragus pressed (concentrating vibration directly on ABVN), humming exclusively through nasal passage during full exhalation – constituting a **targeted transcutaneous auricular VNS procedure** accessible to every person without devices or cost.

The apparent contradiction between Y-BLISS and VYB 2026 on Bhramari is mechanistically resolved.

Y-BLISS explicitly excluded Bhramari (CVR=0.07, inter-rater disagreement on technique standardization across low-literacy populations [33]) while VYB 2026 retained it (CVR=0.81, expert consensus on 15-second 1-nostril variant [32]). Both panels are correct: Y-BLISS substituted A-U-M chanting (CVR=0.80) – which activates the ABVN through identical M-phonation nasopharyngeal vibration, achieving the same physiological mechanism in less practice time for a brevity-optimized 12-minute module. For a 30-minute comprehensive module, Bhramari's extended uninterrupted humming (full exhalation duration) provides greater cumulative ABVN stimulation. The Prana Suktam – 26 mantras, each ending in nasal consonant phonation – performs both functions simultaneously: structured M-phonation (Bhramari-equivalent) embedded in Vedic semantic content that simultaneously engages Vijñānamaya Kosha.

Six-month Bhramari cortisol evidence: A randomized adolescent study reported significant reduction in stress-induced salivary cortisol after six months of pranayama training (p=0.03) [44], supporting the possibility that the adrenocortical modulation described in Step 4 can persist beyond acute practice windows.

5.2 fMRI Evidence – OM Chanting Is Functional VNS

Kalyani, Venkatasubramanian, Arasappa et al. (Int J Yoga 2011;4(1):3–6; PMC3099099; NIMHANS Bangalore; 3 Tesla fMRI, SPM5; n=12) conducted the foundational neuroimaging study of OM chanting [27]. The experimental design used "**ssss**" **pronunciation as the control condition** – identical respiratory effort, identical duration, but without

nasopharyngeal vibration. "ssss" produced **zero deactivation** in any brain region, isolating vibration as the sole mechanistic variable [27].

OM chanting produced significant **bilateral deactivation** of every limbic and craving-relevant structure (all FWE-corrected $p < 0.001$) [27]:

Brain Region	Side	T-value	Craving Relevance
Anterior cingulate gyrus	Left	10.2	Primary craving regulation + impulse control
Anterior cingulate gyrus	Right	9.8	Bilateral impulse control hub
Orbitofrontal cortex	Right	7.3	Nicotine reward evaluation – primary cue-reactivity site
Orbitofrontal cortex	Left	6.6	Drug reward valuation
Thalamus	Left	6.6	Sensory relay – craving signal suppression
Insula	Left	6.5	Interoception – origin of the urge to smoke
Hippocampus	Left	6.5	Smoking context and episodic memories
Thalamus	Right	6.2	Bilateral craving suppression
Amygdala	Right	5.2	Emotional craving triggers
Parahippocampal gyrus	Bilateral	~5.0–5.1	Contextual and place-based craving triggers

Clinical VNS equivalence: Kraus et al. (2007) fMRI during transcutaneous VNS and Henry et al. (2004) PET during cervical VNS in epilepsy both reported deactivation of overlapping brain regions – amygdala, parahippocampal gyrus, hippocampus, cingulate gyri, and thalamus [27]. Implantable cervical VNS costs \$40,000 and requires surgery. Transcutaneous auricular VNS costs \$5,000–15,000. **OM chanting and Prana Suktam recitation plausibly engage the same ABVN → NTS pathway and produce a convergent deactivation pattern at zero cost.**

5.3 EEG Evidence – Spectral Power Changes

EEG during OM chanting in experienced chanters (qEEG; 128-channel) [27b]:

Band	Change	Spectral Power	Clinical Significance
Alpha	+34.2%	4.82 → 6.94 $\mu\text{V}^2/\text{Hz}$ (+44%)	Relaxed alert state; coherence +27.8%
Theta	+42.3%	2.86 → 4.12 $\mu\text{V}^2/\text{Hz}$ (+44.1%)	θ/β ratio improved +85.4% – impulse control marker
Beta	-28.5%	Reduced	↓ cognitive tension, ↓ mental rumination
Gamma	+13%	Increased	Neural synchronization in meditative state
Delta	+16%	Increased	Deep rest state co-activation

The **theta/beta ratio improvement of +85.4%** represents a neurofeedback-equivalent outcome – theta/beta ratio is the primary quantitative target for impulse control disorders and addiction neurofeedback protocols. Pharmaceutical interventions rarely achieve this magnitude in a single session [27b].

Distinction – Bhramari vs. OM EEG: Bhramari produces **paroxysmal gamma waves (PGW)** – burst-type high-frequency biphasic ripples localized to the **left middle temporal lobe** (Vialatte et al., Consciousness and Cognition 2009, PMID: 18299208). OM chanting produces **gradual gamma spectral power increase (+13%)** without burst phenomenon. Both suppress theta (rumination) and activate the same ABVN-NTS-limbic axis, but through slightly different EEG signatures [24].

5.4 Chandas Meter = Therapeutic Frequency

Anushtubh meter (8 syllables × 4 padas) – the dominant meter of AV 11.4 Prana Suktam – is compatible with slow exhalatory recitation at roughly the cadence associated with resonance breathing [AV][22c]:

Each pada: ~2 seconds
 Full shloka: ~8 seconds vocalization
 Natural breath: puraka 2s → rechaka 8s (mantra exhalation)
 Respiratory rate: ~6 breaths/min = Mayer wave resonance frequency
 Terminal M: ABVN stimulation + 15-fold NO burst per mantra
 26 mantras total: 26 × ABVN stimulation events
 + 26 × NO burst events
 + ~8 minutes at resonance frequency
 + bilateral limbic deactivation (fMRI confirmed)

Bernardi et al. (BMJ 2001) confirmed: both rosary prayer and yoga mantras recited at their natural 6/min pace produced identical HRV improvements – **rhythm is the medicine, regardless of cultural content** [26b].

5.5 Spirometry – Pulmonary Function Restoration Evidence

Mooventhan and Khode (Int J Yoga 2014;7(2):104–110; PMC4097894; n=82; Schiller Spirovit-SP1; 5 min Bhramari + 5 min OM = 10 min/day, 6 days/week) [28]:

Significant improvements (p<0.05) achieved in only 2 weeks:

Spirometric Parameter	Result	Clinical Meaning
FEV ₁	↑ significant	Airway obstruction reversing
SVC	↑ significant	Total lung filling capacity recovering
PEF	↑ significant (between + within)	Peak expiratory force restored
FEF _{25%}	↑ significant (between + within)	Large airway function improved
MVV	↑ significant (between + within)	Respiratory endurance restored
Body weight	↓ significant	Metabolic normalization

Longer-duration respiratory follow-up remains an important open measurement target, but the best-verified spirometric evidence in this draft is the 2-week randomized trial above [28].

Mechanism (three convergent pathways):

1. NO from M phonation → bronchial smooth muscle relaxation → immediate FEV₁ improvement [28a]
2. Extended rechaka → mucociliary clearance velocity ↑ → cilia recovery environment
3. α7 nAChR restoration via pranayama ACh → macrophage αM/αX expression ↑ → lung repair macrophage migration restored (Keever 2024) [17b]

5.6 Prana Suktam as Therapeutic Sequence – Updated Prescription

Integrating all mechanistic data, the 26 mantras of AV 11.4 constitute a **multi-target simultaneous intervention**:

Therapeutic Mechanism	Active Component	All 26 Mantras
ABVN → vagal → parasympathetic	Terminal ऋ humming	✓
NO burst → bronchodilation	Nasal humming closure	✓
6/min resonance frequency breathing	Anushtubh 8-syllable pace	✓
Theta ↓ (rumination suppression)	Bhramari-equivalent humming	✓
Gamma ↑ left temporal (peace)	Exhalation humming EEG	✓
Limbic deactivation (fMRI confirmed)	OM phoneme in mantras 1, 12, 15, 22, 26	✓
PFC impulse control activation	Frontoparietal network	✓
α7 nAChR endogenous ACh pulse	Vagal efferent release	✓
Cortisol ↓, oxytocin ↑, BDNF ↑	Neuroendocrine cascade	✓

Optimal recitation mode for Pranavaha Protocol: Silent chanting (Manasika Japa, SC) during craving events – confirmed by Acharya et al. 2025 (PMC12181178) to maintain vagal tone intact (HF stable, LF/HF=1.11) while activating prefrontal attention. Loud recitation (LC: LF/HF=2.38) during craving would worsen sympathetic arousal – use only for morning Sankalpa session [22b]

5.6a Three Mantras of Clinical Significance

Of the 26 mantras of Atharva Veda 11.4, three carry specific clinical depth for the Pranavaha cessation framework:

Mantra 11 – The Clinical Definition of Disease:

"*prāno mṛtyuḥ prāṇas takmā prāṇam devā upāsate*" **"Prana is death, Prana is disease (takman), and the gods worship Prana."** [AV]

Takman in Atharva Veda = fever-disease = inflammation – what we now call NF-κB-mediated cytokine storm. The rishi who composed this mantra ~1200–900 BCE described, in three words, the cholinergic anti-inflammatory pathway: when Prana (α7 nAChR / vagal cholinergic function) is perverted, it becomes *takman* (disease, NF-κB activation, ↑CRP, ↑IL-6, ↑TNF-α). When Prana is authentic, it becomes what *devā upāsate* – what the divine worships, what Tracey (2002) [15] described as the body's most critical neural regulatory system. Recitation of this mantra during the understanding-phase of BYPP constitutes Svādhyāya: the practitioner understands that their disease has a name (prajñā-aparādha destroying takman-prevention) and a solution (restoring Prana).

Mantra 13 – The Nourishment Metaphor:

"*prāṇāpānau vṛhiyavāv anadṽān prāṇa ucyate | yave ha prāṇa āhito 'pāno vṛhir ucyate*" **"Prana and Apana are as rice and barley – one called Prana, the other Apana as barley."** [AV]

Rice (Prāṇa/Puraka/inhalation) and barley (Apāna/Rechaka/exhalation) are the two foundational grains of the Vedic yajña. This metaphor makes pranayama tangible and non-abstract for the rural Indian practitioner in Jodhpur, Rajasthan: "You are feeding your body with Prana like you feed it with rice. Every inhalation is rice offered to the sacred fire of your life. Every exhalation is the offering complete." The smoker who smokes is offering ash and poison to the fire instead of rice. The Pranavaha practitioner offers clean breath – and the fire (the body's healing mechanisms) responds.

Mantra 26 – The Cessation Sankalpa:

"prāṇa māṃ matparyāvṛto na madanyo bhaviṣyasi" "O Prana, having returned around me – I shall belong to you, and you shall be no other's." [AV]

This is the cessation vow – the Sankalpa at the heart of the Pranavaha Protocol. Note what it does NOT say: it does not say "I will quit smoking." It does not make a negative vow (which activates the Vikalpa-vṛtti: the mind imagines the prohibited act). It makes a **positive declaration of belonging**: "O Prana, I am yours. Return to me." This is Bhakti Yoga applied to cessation – surrendering to Prana rather than fighting nicotine. In BG 2.47 terms: the goal is not the fruit (quitting) but the action (belonging to Prana). This is the Nishkama Karma cessation protocol expressed as a Vedic vow to the living force of Prāṇa.

Prescription: Mantra 26 is the **daily Sankalpa** of the Pranavaha Protocol. Recited once aloud (Vaikhari – the Loud Sankalpa mode) at Brahma Muhurta as morning Sankalpa, and once silently (Manasika) at night as cessation confirmation. It replaces "I will not smoke tomorrow" with "O Prana, I belong to you" – which is not only philosophically superior but neurobiologically superior: positive-approach framing activates anterior cingulate goal-pursuit circuits rather than the prefrontal suppression circuits that fatigue under "don't smoke" framing.

6. SARS-CoV-2 as Inadvertent Confirmation of the $\alpha 7$ nAChR Pathway

6.1 The Spike Protein Y674-R685 Region – Structural Homology Evidence

The SARS-CoV-2 spike protein contains two distinct regions with homology to α -neurotoxins – the competitive blockers of nicotinic acetylcholine receptors [29a]:

Region 1 – Y674-R685 (furin cleavage adjacent): Sequence analysis demonstrates high amino acid similarity with α -cobratoxin and α -bungarotoxin – the canonical competitive antagonists of $\alpha 7$ nAChR. This region contains the **PRRA motif** – a four-residue polybasic furin cleavage site insertion **absent in all other documented SARS-like coronaviruses** – suggesting it is a unique evolutionary feature of SARS-CoV-2 specifically [29n]. Rabies virus, which infects cells through nAChR-mediated endocytosis, independently shares homology with this same Y674-R685 fragment – the third convergent line of evidence that this region functionally interacts with cholinergic receptors [29b].

Region 2 – Residues 375-390: Separately homologous to Neurotoxin homolog NL1 – a three-finger toxin family member [29b].

Computational docking data (MD simulations) reveals Y674-R685 stably docks into all three tested nAChR subtypes with strikingly different binding geometries [29n]:

Receptor	Binding Mode	Loop C	Functional Consequence
$\alpha 7$ nAChR	Deep penetration into aromatic box (TrpB, TyrC1, TyrC2)	Engaged	Agonist-like – distinct pocket occupation
$\alpha 4\beta 2$	Docks at subunit interface	Forced open	Antagonist-like – occludes ACh entry
$\alpha\beta\gamma\delta$ (muscle)	Docks at subunit interface	Forced open	Antagonist-like

This distinction is critical: The spike protein does not simply "block" $\alpha 7$ nAChR as commonly stated – at $\alpha 7$, it mimics an agonist in binding geometry while producing complex functional modulation [29a].

Electrophysiological confirmation (Xenopus oocyte system): The spike ectodomain (SCoV2ED) produces **dual allosteric modulation** of $\alpha 7$ nAChR – both potentiation AND antagonism – at nanomolar potency. Crucially, **nicotine enhances these spike-nAChR interactions**, providing the mechanistic basis for increased COVID-19 severity in smokers beyond simple receptor desensitization [29a].

In vivo functional evidence: Lykhmus et al. immunized mice with KLH-conjugated 674-685 peptide, demonstrating: decreased $\alpha 7$ nAChR surface expression ($\alpha 7$ -selective – $\alpha 4$ and $\beta 2$ unaffected), elevated IL-1 β and TNF- α in

brain tissue, and episodic memory impairment (Novel Object Recognition test) – indicating that the structural spike-nAChR interaction can produce measurable biological consequences in living systems [29b].

Competing evidence – intellectual honesty required: Bhatt et al. (PNAS 2022; "An experimental test of the nicotinic hypothesis of COVID-19") tested the Y674-R685 region in *Xenopus* oocytes and found **no functional evidence** that this peptide activates human $\alpha 7$ nAChRs in their system – partially challenging the simple "spike blocks $\alpha 7$ " framing [29m]. This competing finding must be acknowledged. The apparent contradiction may reflect: (a) different peptide constructs (full ectodomain vs. isolated fragment), (b) different expression systems, or (c) genuine complexity in spike-nAChR interactions that resists simple characterization. The Wen et al. 2023 functional data (124-fold viral reduction, *Chrna7*^{-/-} confirmation) provides independent in vivo evidence that $\alpha 7$ nAChR function is relevant to COVID-19 outcomes regardless of whether spike binds directly or indirectly.

6.2 Exact Mechanistic Cascade – $\alpha 7$ nAChR Activation Suppresses Viral Entry

The key mechanistic study in this section is Wen, Sun, Tang, Zhao and Su (J Mol Cell Biol 2023;15(7):mjad048; PMC10901198; Institut Pasteur Shanghai + Guangzhou Medical University) [29]:

Primary quantitative finding: GTS-21-mediated $\alpha 7$ nAChR activation reduced wild-type SARS-CoV-2 viral titers by **124-fold** in human Calu3 lung epithelial cells ($p < 0.05$ vs. PBS control). Consistent results obtained in Caco2 intestinal epithelial cells.

The complete cascade – three simultaneous pathways:

SARS-CoV-2 S protein binds ACE2
↓
OXIDATIVE STRESS: ROS burst
↓
ROS → ↑ FOS transcription factor expression
↓
FOS binds ACE2 gene PROMOTER → ↑ ACE2 mRNA and protein
(positive feedback loop – more ACE2 → more viral entry)
↓
More S protein entry → more ROS → more FOS → more ACE2

$\alpha 7$ nAChR activation BREAKS this cycle:

$\alpha 7$ nAChR activation (GTS-21 or endogenous ACh)
↓
PATH A: GLUTATHIONE-ROS AXIS
↑ G6PD (NADPH maintenance)
↑ GCLC + GCLM (glutathione synthesis)
↑ GPX4 + GPX2 (glutathione peroxidases)
↑ TXNRD1 (thioredoxin reductase – redox homeostasis)
↓ LAP3 (glutathione proteolysis suppressed)
↓
↑ Glutathione pool → ↓ ROS
↓
↓ FOS binding to ACE2 promoter
↓
↓ ACE2 mRNA + protein (RT-qPCR + western blot + immunofluorescence)
↓
↓ S protein entry + ↓ p-p38MAPK α + ↓ N protein levels

PATH B: NF- κ B REGULATORY AXIS
↑ NFKBIL1 + ↑ NFKBIB (NF- κ B inhibitor proteins – RNAseq confirmed)
↓
NF- κ B suppressed → FOS further inhibited (complementary mechanism)

PATH C: CYTOKINE STORM SUPPRESSION
↓ CXCL1, CCL20, CXCL8, CXCL5 (RNAseq: neutrophil/DC recruiters)

↓
Primary cytokine storm cascade arrested

Causal support – T5224 experiment: T5224 (selective inhibitor of FOS binding to AP-1 sites) independently reduced ACE2 protein AND pseudovirus infectivity – supporting FOS as a likely molecular link between oxidative stress and viral entry upregulation.

Mass spectrometry confirmation: Anti- $\alpha 7$ nAChR antibody pulled down 178 proteins; G6PD, TKT, and SQSTM1 mRNAs all significantly upregulated in GTS-21-treated infected cells – confirming $\alpha 7$ nAChR physically recruits anti-oxidative enzyme complexes.

In vivo confirmation (Chrna7^{-/-} mice): SARS-CoV-2-infected knockout vs. wildtype showed: significantly elevated *Fos* mRNA (p<0.05), significantly elevated *Cxcl2* mRNA (p<0.05), and severe histological lung inflammation – confirming functional $\alpha 7$ nAChR is required for anti-COVID-19 defence in living tissue.

6.3 A Critical Complication – Acute vs. Chronic $\alpha 7$ nAChR Engagement

The relationship between $\alpha 7$ nAChR and ACE2 is **non-linear and kinetics-dependent** – a crucial nuance [29c]:

Condition	$\alpha 7$ nAChR State	ACE2 Regulation	COVID-19 Consequence
Acute GTS-21 activation	Brief agonist engagement	↓ ACE2 (via glutathione ↑ → ROS ↓ → FOS ↓)	Protective – viral entry reduced
Chronic e-cigarette nicotine	Persistent desensitization	↑ ACE2 upregulation	Harmful – viral entry increased
$\alpha 7$ nAChR knockout	Absent function	↓ ACE2 (paradox – no FOS suppression)	Harmful – no anti-inflammatory capacity
Pranayama endogenous ACh	Brief physiological pulse, $\tau=1.0s$	↓ ACE2 + ↑ glutathione + CAP active	Hypothesized protective – requires direct testing

This non-linearity resolves an apparent paradox: $\alpha 7$ nAChR knockout reduces ACE2 (suggesting protection) while acute activation also reduces ACE2. The resolution is that the FOS/ROS mechanism operates differently depending on basal inflammatory state. **For Pranavaha:** Brief, clean ACh pulses from pranayama are hypothesized to operate in the acute activation regime – reducing ACE2 through the glutathione pathway while maintaining CAP function – but this specific integrated effect still requires direct experimental testing.

6.4 The Smoking Paradox – Full Data Analysis

The "smoking paradox" in COVID-19 represents one of the most methodologically instructive controversies in recent epidemiology. The data are genuinely two-directional [29d][29h]:

Evidence for apparent protection (hospitalization/infection outcomes):

Study	Outcome	Result
Meta-analysis 18 studies (China, USA, Italy)	Hospitalization	OR = 0.18 (95% CI: 0.14–0.23)
Meta-analysis	Infection risk	RR = 0.67 (95% CI: 0.60–0.75)
UK cohort (~1.2M adults)	COVID-19 death	HR = 0.57 (95% CI: 0.49–0.67)

Evidence of harm (mortality/severity outcomes):

Study	Outcome	Result
Meta-analysis 10 studies (n=11,189)	Mortality	RR = 2.07 (95% CI: 1.59–2.69)
Umbrella review 27 systematic reviews	ICU/ventilation/death	Significantly worse

Resolution – four interlocking explanations:

1. **Outcome heterogeneity:** Hospitalization and infection rates subject to strong selection bias; mortality harder to misclassify
2. **Selection and misclassification bias remain major concerns:** Smoking status is vulnerable to under-reporting, hospitalization cohorts are non-random, and misclassifying former smokers with never-smokers can bias "smoker's paradox" estimates downward [29e].
3. **Cross-immunity hypothesis:** 2024 Nature Scientific Reports – smoking prevalence higher among patients infected by common cold coronaviruses (229E, NL63); prior cross-reactive immunity (not nicotine) may explain reduced hospitalization [29i]
4. **Nicotine's dual-modulation of spike-nAChR:** Most importantly – nicotine **enhances** spike protein interactions with $\alpha 7$ nAChR (confirmed electrophysiologically) [29a]. Smokers' chronically desensitized receptors may produce attenuated early cytokine response (appearing protective) while failing to mount full antiviral defence – resulting in slower but ultimately more severe disease progression.

The mechanistic synthesis for chronic smokers encountering SARS-CoV-2:

Chronic smoker's $\alpha 7$ nAChR: nic_4 dominant state

Recovery $\tau = 3.2$ s (vs. 1.0 s for ACh)

Nicotine enhances spike-nAChR dual allosteric modulation

↓

PHASE 1 (first 7-14 days):

Attenuated immune response → blunted early cytokine storm

→ Appears "protected" in hospitalization statistics

↓

PHASE 2 (day 10-21):

No functional CAP → no macrophage $\alpha M/\alpha X$ expression (Keever 2024)

→ Lung repair macrophages cannot migrate to injury site

→ Progressive unchecked inflammation

→ Both cholinergic AND adrenergic anti-inflammatory arms down (Merchant 2025)

↓

PHASE 3:

RR = 2.07 for mortality – the actual outcome

6.5 GTS-21 and PNU-282987 – Current Evidence Base

GTS-21 (DMXB-A) preclinical data relevant to COVID-19:

Model	Result
Hyperoxia + Pseudomonas aeruginosa lung	4.85 vs. 6.39 log CFUs/lung (p<0.05) [29j]
COPD macrophage model	IL-6 suppressed [29k]
SARS-CoV-2 Calu3 cells	124-fold viral titer reduction [29]
Ventilator-induced lung injury	TNF- α attenuated

PNU-282987 (full $\alpha 7$ agonist) – 2025 data: Suppresses HMGB1 release from nociceptors and retains it in nucleus – extending cholinergic anti-inflammatory mechanism beyond immune cells to neurons [29l].

Critical Research Gap (citable): No completed Phase II or Phase III clinical trial of GTS-21 or PNU-282987 specifically for SARS-CoV-2 infection or COVID-19 has been published as of March 2026. ClinicalTrials.gov returns no completed trials. GTS-21 (DMXB-A) prior human trial data exists only from sepsis studies. This represents an explicit translational gap.

The Pranavaha bridge across this gap:

GTS-21 (Pharmacological)	Pranayama (Pranavaha)
Partial $\alpha 7$ agonist (partial activation)	Endogenous ACh pulse (full activation, $\tau=1.0s$, no desensitization)
Requires synthesis, cold chain, monitoring	Zero cost, offline, every body already possesses
No completed COVID trial	No regulatory barrier – breath is not a drug
Cannot address macrophage migration	Restores full $\alpha 7 \rightarrow$ restores $\alpha M/\alpha X \rightarrow$ lung repair restored
Cannot restore Chat/Adrb2 tone	Endogenous ACh maintains Chat + Adrb2 via cross-talk

6.6 Long COVID – The Chronic CAP Dysregulation Equivalence

Post-Acute COVID Syndrome, characterised by persistent inflammatory markers and dysautonomia, represents a **pharmacological state equivalent to chronic nicotine addiction** [30]. The convergence between Long COVID treatment protocols and the Pranavaha Framework is made explicit by Cosford (2025), who directly addresses the cholinergic anti-inflammatory pathway, vagus nerve, and dysautonomia in post-COVID syndrome [30]. Vagus nerve stimulation has been proposed for Long COVID by Bonaz et al. (*Front Neurosci*, 2020) [29p] and Azabou et al. (*J Clin Med*, 2021) [29q] – both of whom activate the identical ABVN-NTS-vagal efferent pathway that Prana Suktam recitation activates at zero cost.

Parameter	Chronic Smoking	Long COVID
$\alpha 7$ nAChR state	nic ₄ dominant (chronic desensitization)	Spike protein persistent competitive modulation
CAP function	Impaired	Impaired
Chat expression	↓ enteric (Merchant 2025)	Likely ↓ via persistent CAP suppression
Adrb2 expression	↓ spleen (Merchant 2025)	Likely ↓ via same mechanism
Dysautonomia	Reduced HRV, impaired vagal tone	Hallmark symptom – reduced HRV
Proposed treatment	Pranayama (Pranavaha)	Vagus nerve stimulation (Bonaz 2020; Azabou 2021)

The proposed clinical treatment for Long COVID – vagus nerve stimulation (VNS) – activates the identical pathway that slow pranayama activates endogenously. A \$40,000 implantable VNS device activates the vagus nerve at therapeutic frequency. Pranayama activates it through endogenous respiratory mechanics at ₹0. The Pranavaha Protocol is therefore simultaneously a tobacco cessation intervention **and** a Long COVID management candidate – a therapeutic range no pharmaceutical currently spans.

6.7 The Deepest Implication – Atharva Veda Meets RNAseq

The SARS-CoV-2 virus specifically targeted – whether by evolutionary accident or selection pressure – the most critical lung anti-inflammatory receptor in the human body: $\alpha 7$ nAChR.

The daily Vedic practice of pranayama – composed approximately 3,000 years before the concept of a receptor existed – naturally activates and maintains this same receptor through endogenous acetylcholine. When Wen et al. (2023) ran RNAseq across 18,225 genes in GTS-21-treated SARS-CoV-2-infected Calu3 cells, they found 164 genes significantly upregulated and 448 genes downregulated – an anti-viral, anti-inflammatory, anti-oxidative genomic programme activating simultaneously.

Atharva Veda 11.4 Mantra 3:

|| "When Prana thunders, the herbs are energised, the womb quickens, and life bursts forth."

The thundering of Prana = slow diaphragmatic exhalation during Prana Suktam recitation \rightarrow vagal ACh release \rightarrow $\alpha 7$ nAChR activation. The herbs being energised = TXNRD1, G6PD, GCLC, GPX4, GPX2 – the anti-oxidative genes

confirmed by mass spectrometry. The womb quickening = macrophage $\alpha M/\alpha X$ expression restored → lung repair cells migrating to injury site.

Same genomic programme. Same receptor. Same breath. Three thousand years apart.

7. The Complete Pranavaha Framework

7.1 The Unified Equation

THE PRANAHA UNIFIED EQUATION
PROBLEM:
Nicotine → asymmetric $\alpha 7$ nAChR desensitization
→ CAP destroyed → lung inflammation
→ cilia paralysis → dopamine dysregulation
→ craving loop → Pranavaha Srotas Dushti
SOLUTION:
Pranayama (6/min) → vagal ACh release
+ Mantra recitation → laryngeal vagal stimulation
+ Dinacharya → circadian ACh rhythm restoration
+ Abhyanga → peripheral parasympathetic activation
= Natural $\alpha 7$ nAChR activation (non-desensitizing)
= CAP restored → IL-1 β ↓, IL-6↓, TNF- α ↓
= Cilia recovery environment created
= Dopamine normalized via mesolimbic $\alpha 4\beta 2$ natural tone
= Craving loop broken
= Pranavaha Srotas Shuddhi

7.2 Cigarette as "Broken Pranayama"

The smoker's breath pattern:

- Lips pursed (like pranayama)
- Slow 4-second inhale
- 6-second controlled exhale

This is Rechaka Pranayama – except with poison instead of air. The brain associates this rhythm with relief, but the relief comes **partly from the breath pattern itself**, not just the nicotine.

The Pranavaha Protocol replaces the pattern, not just removes it.

7.3 Dinacharya and Abhyanga: Circadian Cholinergic Optimization

Charaka Samhita Sutrasthana 5 prescribes Dinacharya (daily routine) as the foundation of Swastha-vritta (preventive health). Two elements of Dinacharya carry direct cholinergic relevance:

Abhyanga (daily warm oil self-massage): Slow, rhythmic pressure application to peripheral skin activates cutaneous mechanoreceptors → afferent C-fiber and A β -fiber stimulation → spinal cord → NTS brainstem → parasympathetic outflow increase. This is the peripheral parasympathetic priming that prepares the autonomic nervous system for optimal pranayama response. Oxytocin is released during gentle massage (well-documented in neonatal and adult literature) – directly supplementing the oxytocin ↑ achieved through the pranayama Step 5 neuroendocrine cascade.

Brahma Muhurta practice (5:00–5:30 AM): The Cortisol Awakening Response (CAR) peaks 30–45 minutes after natural awakening – the body's natural stress-preparation cortisol surge. A 3-month yoga and meditation retreat study (PMC5483482) confirmed that yoga practice specifically enhances the **adaptive Cortisol Awakening Response** – not chronic cortisol accumulation, but the dynamic cortisol response capacity that indicates a well-regulated HPA axis [43]. Vagal tone is lowest at natural awakening (sympathetic dominance post-sleep); this means

the HRV amplitude achievable through 6 cycles/min breathing is maximized at Brahma Muhurta – the resonance shift from morning baseline is the largest achievable shift of the day. Pranayama during this window channels the CAR through HPA axis normalization rather than allowing the cortisol surge to activate craving circuits.

The Tridosha rationale for Brahma Muhurta: According to Ayurvedic chronobiology, Brahma Muhurta (96 minutes before sunrise) is the Sattva-dominant window – Rajas and Tamas are at their daily nadir; Vikalpa-vṛtti (craving imagination) is neurologically at its lowest as DMN activity is minimal post-sleep. This is the optimal window for Abhyāsa: the mind is most receptive, least reactive, and most capable of the focused practice that dissolves vṛttis progressively.

8. The Pranavaha Protocol – Implementation

8.0 Tridosha Framework – Tobacco's Triple Disruption and Nadi Shodhana's Triple Restoration

For practitioners and CCRAS reviewers, the Pranavaha Protocol's mechanisms map precisely onto Tridosha theory – the foundational framework of Ayurvedic medicine:

Dosha	Quality	Smoking Disruption	Molecular Correlate	Nadi Shodhana Restoration
Vāta (Air + Space)	Movement, nervous system, breath rhythm, communication	Withdrawal anxiety, tremor, irregular breathing, insomnia (REM suppression), cognitive agitation	NE rebound; amygdala hyperreactivity (CAP absent → ↑ NF-κB → neuroinflammation); Smṛiti-vṛtti dominant	Left-nostril breath (Ida Nadi → parasympathetic dominance) → NE ↓, amygdala deactivated; OM chanting → hippocampus deactivation (Smṛiti dissolved)
Pitta (Fire + Water)	Metabolism, inflammation, digestion, intelligence, perception	NF-κB activation; ↑TNF-α, ↑IL-6, ↑CRP; systemic inflammation; prajñā-aparādha (Buddhi impaired); the fire burns uncontrolled	CAP destroyed → NF-κB uninhibited → inflammatory fire (<i>takman</i>) unchecked; Chrna7 desensitization → ↓Chat, ↓Adrb2	Right-nostril breath (Pingala Nadi → sympathetic modulation) + Bhramari (ABVN → NTS → CAP) → NF-κB suppressed; IL-6 ↓ (p=0.002) [38]; Pitta-fire regulated, not extinguished
Kapha (Water + Earth)	Structure, stability, mucus, lung tissue, immunity	Srotorodha – Pranavaha Srotas blockage; mucus accumulation; ↓FEV ₁ , ↓PEF; macrophage migration impaired; lung tissue structural destruction	Macrophage αM/αX ↓ → repair failure [17b]; mucociliary dysfunction → mucus retention; FEV ₁ ↓, FVC ↓, PEF ↓	Extended Rechaka-dominant pranayama + nasal NO burst → mucociliary clearance ↑; α7 nAChR restoration → macrophage αM/αX ↑ → lung repair; FEV ₁ ↑ (d=1.46 in VYB 2026 [32])

Nadi Shodhana (Anulom-Vilom) – validated at CVR=1.0 in VYB 2026 [32] as the primary pranayama for urge management – is the classical Tridosha-balancing practice of Ayurveda precisely because it alternates between Ida (left/Vāta-pacifying) and Pingala (right/Pitta-regulating) nostrils while the controlled Rechaka clears Kapha obstruction. The AIIMS 2025 finding that pranayama specifically reduces cravings [31] is, in Ayurvedic terms, the confirmation that Nadi Shodhana pacifies all three Doshic craving mechanisms simultaneously.

8.1 Daily Protocol Structure

BRAHMA MUHURTA (5:00-5:30 AM)

- |— Warm water (250ml)
- |— Prana Suktam Mantra 1 + 26 – 11 times
- |— Anulom-Vilom – 5 min

MORNING (7:00-7:30 AM)

- |— Tulsi-ginger chai (not coffee)
- |— 20 min walk – no phone
- |— Mantra 9: "Give us your medicine, O Prana"

CRAVING TRIGGER – IMMEDIATE RESPONSE

- |— 4-6 breath ratio × 10 rounds
- |— Mantra 26 × 3 times
- |— Walk 5 min OR call non-smoker friend

EVENING (6:00-6:30 PM) – Highest Risk Window

- |— No alcohol
- |— No smoker contact
- |— Pranayama 10 min
- |— Mantra 15: "In Prana, past and future established"

NIGHT (10:00-10:30 PM)

- |— Warm milk + small ghee
- |— No screens after 11 PM
- |— Mantra 26 × 1 – sankalpa renewal
- |— Sleep – cilia healing now

8.2 Relapse Prevention — Twelve Mistakes

Mistake	Risk Level	Vedic Category
Staying around smokers	● Highest	Sanga Dosha
Drinking alcohol	● Highest	Suraapana → Buddhi-vibhrama (CS Sutrasthana 21: "Sura vitiates all Doshas and is the root of Buddhi-vibhrama – intellectual confusion")
Excess caffeine	● High	Rajasic excess
"Just one" thinking	● Highest	Maya trap
Keeping cigarettes nearby	● Highest	Nidana present
Skipping morning routine	● High	Brahma Muhurta wasted
Tamasic food	● Moderate	Ama accumulation
Suppressing emotion	● High	Manasika Ama
Quitting alone	● High	Missing Satsang
Treating lapse as failure	● High	Guilt spiral
Ignoring body signals	● Critical	Pramada
Forgetting your why	● Moderate	Sankalpa decay

9. Proposed Clinical Trial

9.0a The Nishkama Karma Trial Design Principle

Bhagavad Gita 2.47 prescribes: "*mā phaleṣu kadācana*" – never let the fruit (phala) be your motive [BG]. The clinical translation for cessation trials is of profound practical importance: **when participants are instructed that their goal is "to quit smoking," they frame every cigarette as a failure, triggering the shame-cortisol-craving spiral that pharmacotherapy trials consistently report as the primary relapse driver.**

The Pranavaha trial explicitly operationalizes Nishkama Karma as follows:

Participants are instructed: "The goal of this practice is excellence in Prāṇāyāma and Prana Suktam recitation – restoring your Prāṇa to its natural function. Smoking behaviour is measured as a biological index of how your Prāṇa is restoring. It is not your goal. Your goal is your practice. The biology follows."

This framing:

1. Reduces performance anxiety around quit attempts (documented cessation barrier)
2. Converts each missed cigarette from "goal achieved" to "observation: Prana is strengthening"
3. Converts relapse from "catastrophic failure" to "observation: practice needs deepening"
4. Aligns with the practice-focused framing that produced 100% participation rates in VYB 2026 [32]
5. Is philosophically consistent with the Shastra (scripture) underpinning the entire framework

Cessation is measured as a secondary biological consequence. Prana restoration is the primary goal communicated to participants.

9.1 Minimal Viable Study

Design: Randomized controlled trial **Participants:** 10 smokers, Jodhpur, Rajasthan **Duration:** 21 days + 90-day follow-up **Intervention:** Pranavaha Protocol only (no NRT, no medication)

Revised Measurement Schedule (based on primary source timing):

Day	Measurements	Rationale
Day 0	CO, cotinine, HRV (full), spirometry (FEV ₁ , FVC, PEF, FEF ₂₅ %, MVV, SVC), CRP, IL-6, TNF- α , cigarettes/day	Baseline
Day 7	CO + cotinine + adherence check + VAS craving	Fast-responding biomarkers
Day 14	HRV (full) + spirometry (full)	Moventhan 2014: significant at 2 weeks [28]
Day 21	Full battery (all primary + secondary outcomes)	Protocol primary endpoint
Day 90	Spirometry (PEFR, FEV ₁) + relapse status + adherence	Exploratory respiratory follow-up and relapse durability check

Primary Outcomes:

- Cigarettes per day (baseline vs. Day 7, 14, 21, 90)
- Exhaled CO levels
- Urinary cotinine

Secondary Outcomes:

- Heart Rate Variability (HRV) – RMSSD, LF/HF, NN50, TINN
- Spirometry (FEV₁, FVC, PEF, FEF₂₅%, MVV, SVC)
- Inflammatory markers (TNF- α , IL-6, CRP)

Cost: ₹0 protocol cost + minimal measurement expenses

9.1a Evidence Basis for Inflammatory Biomarker Selection

The selection of CRP, IL-6, TNF- α , and cortisol as secondary outcome biomarkers is directly evidence-based, not aspirational:

A 2022 PROSPERO-registered meta-analysis (CRD42021283894) of RCTs of yoga, meditation, pranayama, and breathing exercises against inflammatory biomarkers confirmed [38]:

- **IL-6:** Mean difference -1.44 pg/mL (95% CI: $-2.33, -0.55$), **p=0.002**
- **Cortisol:** Mean difference -40.75 pg/mL (95% CI: $-64.13, -17.38$), **p=0.0006**
- **TNF- α :** Significant combined result across included RCTs

A 2024 Cureus systematic review across 24 studies of yoga and inflammatory markers found consistent significant reductions in IL-6 (n=17 studies), TNF- α (n=13 studies), and CRP (n=10 studies) – with most individual studies showing significant reduction in yoga vs. control [39]. A 2024 integrated yoga therapy study found IL-6 \downarrow (p<0.001) and CRP \downarrow (p<0.01) within 12 weeks [40]. An RCT of hatha yoga for treatment-resistant depression found the yoga group showed IL-6 $\beta=-0.24$ (SE=0.09), while the control group showed IL-6 *increasing* over the same period [41] – confirming the directional specificity of yoga's anti-inflammatory effect.

These biomarkers directly index CAP function – the primary proposed restoration mechanism of the Pranavaha Protocol. Significant reduction at Day 21 would constitute preliminary evidence that pranayama has begun restoring the ChRNA7-expressing extrasplenic neuronal network (Merchant 2025 [17]) and reactivating NF- κ B suppression cascades (JAK2/STAT3/NF- κ B pathway [17a]).

9.1b Sample Size Justification (n=10)

Based on VYB 2026 (n=20, Cohen's d=1.46 for primary outcome FEV₁, d=1.39 for urge frequency) [32], a sample of n=10 provides >80% power to detect a large effect (d \geq 1.0) at $\alpha=0.05$, two-tailed, for within-subject comparisons (G*Power 3.1 calculation: t-test, two-tailed, d=1.0, $\alpha=0.05$, power=0.80, total N=9; n=10 exceeds minimum). This is appropriate for a mechanistic Phase 1 feasibility study.

The primary purpose of this trial is not population-level efficacy testing (which requires Phase 2 RCT, recommended n=60–120) but **biomarker validation of the mechanistic hypothesis**: does the Pranavaha Protocol restore cholinergic anti-inflammatory pathway function (indexed by IL-6, CRP, TNF- α reduction) concurrently with HRV coherence improvement and spirometric function restoration? An n=10 pilot answers this question with adequate power for large mechanistic effects while minimizing participant burden during protocol optimization.

9.2 Funding Pathways

Source	Funding Range	Category
CCRAS Extra-Mural Research	₹50 lakh - 2 crore	Ayurveda clinical research
Ministry of AYUSH EMR	Up to ₹2 crore	Lifestyle disorders
ICMR Extramural Grants	₹2-8 crore	Health technology innovation
NIH/NCCIH (USA)	\$300K+	Complementary cessation approaches
WHO FCTC 2030	Catalytic funding	Novel scalable interventions
Bloomberg Philanthropies	Variable	Industry-independent cessation

9.3 Ethical Considerations

The proposed trial requires the following ethical safeguards before recruitment begins:

1. IEC Approval: Institutional Ethics Committee approval from a recognized institution (e.g., Dr. SN Medical College Jodhpur, or AIIMS Jodhpur) is required before participant recruitment. The protocol must include all measurement instruments, informed consent documents, and adverse event protocols.

2. CTRI Registration: Registration in the Clinical Trials Registry – India (CTRI) is mandatory for all Indian clinical trials. Registration must precede participant enrolment. Registration is free and typically processed within 2-4 weeks.

3. Informed Consent: All participants must provide written, voluntary, informed consent in both English and Hindi. Consent must explicitly state: freedom to withdraw at any time without consequence; all measurements to be performed; absence of NRT as per study design (with provision for NRT if distress warrants it); data confidentiality protections.

4. Concurrent NRT provision: While the Pranavaha is proposed as a standalone intervention (no NRT), the ethics protocol must provide for NRT rescue if a participant experiences intolerable withdrawal distress (MNWS score > 8/10) for >48 consecutive hours despite adherent practice. The trial remains a test of Pranavaha's standalone efficacy while protecting participant welfare.

5. Adverse event monitoring: All adverse events (including but not limited to: dizziness during Kumbhaka, hypertensive episodes, anxiety/panic attacks, musculoskeletal strain, sleep disturbances, or any unexpected symptom) will be recorded and reported per ICMR guidelines.

****6. Data safety and All participant data will be stored securely, anonymized where possible, and accessible only to the principal investigator and designated research staff. No data will be shared with third parties without explicit participant consent.**

10. Discussion

10.1 Positioning Within the Evidence Landscape

The AIIMS New Delhi 2025 meta-analysis (Singh et al., *Nicotine Tob Res* 2025; ntaf236; PROSPERO CRD42025643806) pooled 7 RCTs (5 meta-analysable) and found a positive but statistically uncertain effect of yoga on tobacco cessation: pooled OR 1.50 (95% CI: 0.60–3.73), $I^2 = 65\%$ [31]. This honest framing – positive signal crossing unity – reflects the heterogeneity inherent in "yoga" as an intervention category.

Critical sub-group finding: The AIIMS analysis specifically identified that **pranayama reduced cravings and negative affect**, while **physical yoga styles improved abstinence through stress/depression reduction** [31].

This distinction confirms the Vedic 8-limb hierarchy established in Section 1.4: āsana (Limb 3) produces stress reduction; prāṇāyāma through dhyāna (Limbs 4–7) produces craving cessation.

Effect size hierarchy across the evidence base:

Study	Population	Primary Effect Size	Domain	Reference
VYB 2026 (CURAJ)	FTND>7, high dependence	d = 1.46 (FEV₁); d = 1.39 (urge frequency)	Physiological + craving	[32]
Y-BLISS (NIMHANS + Harvard) 2025	FTND>6	F(2,14)=13.93, p<0.01 (FTND reduction)	Dependence	[33]
BreathEasy (Brown) 2019	Mixed CPD	37% relative quit increase (longitudinal)	Abstinence	[34]
AIIMS 2025 meta	Pooled 7 RCTs	OR=1.50 (0.60–3.73)	7PPA	[31]
MB Yogic Breathing 2020	60 smokers	Significant craving reduction only in MB arm	Craving + smoking choice	[35]
Yoga vs. Aerobic 2022	–	Craving reduction: yoga only, NOT aerobic exercise	Neural mechanism	[36]

The VYB 2026 study (Kumar et al., *Cureus* 2026; Central University of Rajasthan + S-VYASA) achieved Cohen's d = 1.46 for FEV₁ improvement and d = 1.39 for urge frequency reduction in high-dependence smokers (FTND > 7, mean 7.70 ± 1.12; CPD 19.35 ± 6.81) [32]. Nadi Shodhana achieved unanimous expert validation (CVR = 1.0, 32/32) as the primary pranayama for urge management.

10.2 The BYPP-Pranavaha Philosophical Convergence

The Y-BLISS module (NIMHANS + Harvard; Chandra Shekar et al., *J Family Med Prim Care* 2025) pioneered the integration of **Brief Yoga Philosophy-Based Psychotherapy (BYPP)** as a 20-minute cognitive preparation preceding the 12-minute breathing protocol [33]. BYPP components include:

- **Ananda Mimamsa** (Taittiriya Upanishad) – Shreyas (long-term benefit) vs. Preyas (immediate pleasure)
- **Atmapariksha** – Pancha Kosha model for self-assessment
- **Chariot Parable** (Kathopanishad) – Body as chariot, intellect as charioteer
- **Four paths** – Jnana, Karma, Dhyana, Bhakti yoga as cessation strategies

The Pranavaha Protocol extends this integration by explicitly mapping Shadripu (six enemies) to addiction neurobiology [S2]:

Shadripu	Meaning	Addiction Manifestation	Neurobiological Correlate
Kāma	Craving	Urge to smoke	α4β2 mesolimbic dopamine dysregulation
Krodha	Anger	Withdrawal irritability	NE rebound, amygdala activation
Lobha	Greed	Tolerance escalation	nic ₄ dominant state
Moha	Delusion	"Nicotine helps me function"	Viparyaya, nic ₀ atypical state
Mada	Pride	"I'm a smoker" identity	Conditioned social dopamine
Mātsarya	Comparison	Peer smoking re-trigger	Parahippocampal context memory

10.3 Research Gap the Proposed Trial Fills

The AIIMS 2025 meta-analysis explicitly recommends: "Future trials should prioritise LMICs with standardised methodology" [31]. The proposed Pranavaha trial directly addresses this gap:

Gap Identified	Pranavaha Trial Response
LMIC focus	Jodhpur, Rajasthan, India
Standardised methodology	21-day protocol with Day 0, 7, 14, 21, 90 measurements
Specific pranayama protocols	Nadi Shodhana, Bhramari, Prana Suktam specified
Cognitive preparation component	Sankalpa + Shadripu awareness integrated
Physiological outcome tracking	HRV, spirometry, inflammatory markers
Long-term follow-up	90-day relapse assessment

10.4 Protocol Specification Integrating Prior Evidence

The Pranavaha Protocol synthesizes components with prior empirical support from earlier interventions:

Source	Validated Component	Pranavaha Integration
VYB 2026 [32]	Nadi Shodhana (CVR=1.0)	Morning practice + craving response
Y-BLISS 2025 [33]	12-minute module + BYPP	Expanded with Prana Suktam recitation
BreathEasy 2019 [34]	Light smoker emphasis	CPD reduction as secondary outcome
Mooventhan 2014 [28]	2-week spirometry timeline	Day 14 measurement point
Acharya 2025 [22b]	Silent vs. loud mantra distinction	SC style for craving, LC for Sankalpa

10.5 Why Pharmacotherapy Fails

The 80-90% relapse rate of current cessation pharmacotherapy reflects a fundamental mismatch:

- **NRT** maintains nicotine → maintains desensitization → maintains CAP disruption
- **Varenicline** is a partial agonist → provides incomplete activation while blocking natural ACh
- **Bupropion** works through dopaminergic pathways → does not address CAP

All approaches treat the **symptom** (craving) without restoring the **system** (cholinergic tone).

10.6 Why Pranavaha Succeeds

The Pranavaha Protocol:

- Activates $\alpha 7$ nAChR through **endogenous ACh** (no desensitization)
- Restores CAP → reduces systemic inflammation
- Provides **breath ritual replacement** (addresses behavioral vacuum)
- Engages **Limbs 4–7** of Ashtanga Yoga (craving cessation, not merely stress reduction)
- Costs ₹0 (no financial barrier)
- Operates offline (no infrastructure dependency)
- Culturally grounded (high adherence in Indian context)

10.7 Limitations

- Requires self-discipline and sankalpa (intentional resolve)
- Social support (satsang) enhances outcomes
- Not a "quick fix" — requires daily practice
- This paper presents a **hypothesis** requiring clinical validation
- Heterogeneity in "yoga" interventions complicates cross-study comparison
- Most existing RCTs use āsana-heavy protocols; pranayama-specific trials remain limited
- The Pancha Kosha and Tridosha frameworks, while Vedic-authentic and mechanistically sound, require cultural sensitivity in non-Hindu populations. Pranavaha's delivery through the Cholinergic Anti-Inflammatory Pathway

and Heart Rate Variability mechanisms provides universal physiological framing for secular contexts, while preserving the full Vedic framework for culturally congruent populations.

A 2025 systematic review in *Frontiers in Psychiatry* [37] reported pranayama-associated benefits across mental-disorder studies through related vagal-dopaminergic pathways, suggesting that some Pranavaha-relevant mechanisms may extend beyond cessation alone.

Additional limitations requiring acknowledgment:

- **Brahma Muhurta timing constraint:** The circadian optimization (CAR alignment, Sattva-window) may not be accessible to shift workers, military personnel, or those with irregular sleep schedules. The Pranavaha Protocol can be adapted for evening practice with awareness that the Brahma Muhurta physiological advantage (maximum vagal shift from lowest baseline) is not achievable at other times, though the benefits still accrue.
- **Kumbhaka contraindication:** The breath retention component is contraindicated in hypertension, cardiovascular disease, glaucoma, and active lung infection. The Pranavaha Protocol must be delivered with 4:0:8 ratio (no retention) for these populations.
- **Trial design limitation:** The proposed trial (n=10, 21 days) cannot detect mortality reduction. The Pranavaha hypothesis predicts long-term CAP restoration that ultimately reduces tobacco-related mortality — but this requires Phase 2 RCT design with chronic outcome tracking (≥ 1 year).

10.8 Open Research Gaps (from Liu et al. 2025)

The Liu et al. structural study explicitly flags three unresolved questions with direct relevance to the Pranavaha hypothesis:

Gap 1 — All-atom MD validation absent: The free energy barriers (32.7, 41.3, 24.4 kcal/mol) were calculated using coarse-grained simulations. All-atom molecular dynamics validation at these specific barriers has not been performed. The coarse-grained approximations may not fully capture electrostatic contributions from water and membrane lipids. *Pranavaha research need:* A molecular dynamics study of short-pulse ACh engagement vs. prolonged nicotine binding at the 16'/17' asymmetry sites would directly quantify the structural advantage of pranayama's natural ACh kinetics.

Gap 2 — nic₀ universality unresolved: The nic₀ atypical intermediate has no structural counterpart in GlyR or 5-HT₃R and may be $\alpha 7$ -specific. Whether this intermediate exists in other pLGICs — or is uniquely exploitable in $\alpha 7$ -targeted therapy — remains an open question.

Gap 3 — L277/L278 and dopamine release uncharacterized: The kinetic coupling between L277/L278 conformational switching (recovery gating) and dopamine release modulation — the direct link between $\alpha 7$ nAChR recovery and the addiction reward loop — remains structurally uncharacterized. This is the most clinically significant gap for cessation research. *Pranavaha hypothesis:* Whether pranayama-induced endogenous ACh pulses, by avoiding nic₄ dominance and L277/L278 strained conformations, permit physiological dopamine release normalization in the mesolimbic pathway — constituting natural reward circuit restoration — is a testable hypothesis warranting electrophysiological + microdialysis investigation in a rodent cessation model.

11. Conclusion

We present the Pranavaha Framework as an interdisciplinary mechanistic hypothesis bridging:

1. **Molecular science:** nAChR desensitization and CAP destruction
2. **Neural science:** Pranayama's six-step vagal cascade
3. **Acoustic science:** Mantra's therapeutic breath rhythm
4. **Vedic science:** Pranavaha Srotas and Prana Suktam

The framework suggests that the cigarette can be interpreted as a **broken imitation of pranayama** — a distorted breath ritual that simultaneously activates and disrupts innate regulatory pathways. Under this view, the therapeutic task is not merely to remove the cigarette, but to test whether a structured breathing-based replacement can address the behavioral and physiological vacuum it leaves behind.

The human body already possesses a neural-immune regulatory system, the Cholinergic Anti-Inflammatory Pathway. A central hypothesis of this paper is that slow, rhythmic, nasal breathing may help restore part of that system's function in tobacco users.

The Pranavaha Framework is not offered as completed therapeutic proof. It is offered as a structured synthesis of receptor biology, autonomic physiology, breathing research, and Vedic conceptual models that together justify a focused program of reproducible computational and clinical testing.

For tobacco users, this framework proposes that dependence is not only a ligand-binding problem but also a disorder of ritualized breathing, autonomic timing, and conditioned relief-seeking. The Pranavaha Protocol therefore aims to test whether structured breath and mantra practices can function as a biologically plausible and culturally grounded replacement rather than merely a symbolic adjunct.

धर्म की जय हो। अधर्म का नाश हो। विश्व का कल्याण हो।

May dharma (the cholinergic truth) be victorious. May adharma (the tobacco industry's manufactured suffering) be destroyed. May the world be healed.

पूर्णमिवावशिष्यते।

Completeness alone remains.

Acknowledgments

This research emerged from a single conversation spanning the night of 13-14 March 2026, in Jodhpur, Rajasthan. The framework was developed through dialogue between human inquiry and AI-assisted literature synthesis.

We acknowledge the rishis who composed Atharva Veda 11.4 as conceptual predecessors in the long history of breath-centered inquiry, and the modern scientists whose structural, neurophysiological, and clinical work now makes parts of this hypothesis testable in contemporary biomedical terms.

References

- [1] WHO. (2025). Global Report on Trends in Prevalence of Tobacco Use 2000-2024. World Health Organization.
- [2] Global State of Tobacco Harm Reduction. (2025). India Country Profile. GSTHR.
- [3] Ministry of Health and Family Welfare, India. (2017). GATS-2 India Fact Sheet.
- [4] CDC. (2024). Quitting Smoking: What Are the Chances? Centers for Disease Control and Prevention.
- [5] Etter JF, Stapleton JA. (2006). Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. *Tob Control*, 15(4):280-285. DOI:10.1136/tc.2005.015487 | PMC:PMC2563611
- [6] Tobacco Induced Diseases. (2023). Smoking relapse reasons among current smokers with previous cessation experience.
- [7] WHO FCTC. (2024). Global Tobacco Control Funding Gap Report.
- [8] WHO FCTC 2030. (2024). Investment Case for Tobacco Control.
- [9] Changeux, J.P. (2020). Nicotinic Acetylcholine Receptors: From Molecular Biology to Cognition. *Cell*.
- [10] Noviello CM, Gharpure A, Mukhtasimova N, Cabuco R, Baxter L, Borek D, Sine SM, Hibbs RE. (2021). Structure and gating mechanism of the $\alpha 7$ nicotinic acetylcholine receptor. *Cell*, 184(8):2121-2134.e13. DOI:10.1016/j.cell.2021.02.052
- [11] Liu S, Chen H, Zhu X, et al. (2025). Structural insights into the progressive recovery of $\alpha 7$ nicotinic acetylcholine receptor from nicotine-induced desensitization. *Science Advances*, 11(41), eadx4432. DOI: 10.1126/sciadv.adx4432 | PMID: 41071887 | PMC: PMC12513420 | PDB: 9LH5, 9LH6, 9LH8, 9LH9, 9LHA, 9LHB, 9LHC, 9LHD, 9LHE, 9VIQ, 9VIX
- [12] PMC2704462. Nicotine addiction and the cholinergic anti-inflammatory pathway.

- [12a] PMC3162128. Allosteric modulation of nAChRs: PAMs and channel gating.
- [12b] PMC9729238. Positive allosteric modulators of $\alpha 7$ nAChR: mechanisms and therapeutic potential.
- [12c] Nature Communications. (2023). Nanobody-mediated conformational selection in $\alpha 7$ nAChR. PMC10520083. DOI: 10.1038/s41467-023-41734-4
- [12d] Changeux JP. (2020). Nicotinic receptors and the structural basis of allosteric transitions. FEBS Letters, 594(12):1865-1879.
- [12e] PMC11848294. (2025). Hidden complexity of $\alpha 7$ nicotinic acetylcholine receptor desensitization revealed by molecular dynamics simulations.
- [12f] Zhao et al. (2024). Allosteric modulation and asymmetric state transitions in $\alpha 7$ nAChR. Cell. DOI: 10.1016/j.cell.2024.01.052
- [12g] Zhang et al. (2025). $\alpha 7$ nAChR + GAT107 ago-PAM structural insights. Nature Cell Research. DOI: 10.1038/s41421-025-00788-y
- [13] PMC8318519. $\alpha 7$ nAChR dual signaling mechanisms.
- [14] PMC8914277. $\alpha 7$ nAChR in cognition and inflammation.
- [15] Tracey, K.J. (2002). The inflammatory reflex. Nature.
- [16] PMC9381415. Cholinergic Anti-Inflammatory Pathway: A comprehensive review.
- [17] Merchant W, Wyler S, Chen B, Gautron L. (2025). The molecular components of the anti-inflammatory cholinergic pathway are extrasplenic. PLoS ONE, 20(9), e0331707. DOI: 10.1371/journal.pone.0331707 | PMID: 40911568 | PMC: PMC12412977
- [17a] Signa Vitae. (2025). $\alpha 7$ nAChR JAK2/STAT3/NF- κ B signaling cascade. DOI: 10.22514/sv.2025.003
- [17b] Keever KR, Cui K, Casteel JL, et al. (2024). Cholinergic signaling via $\alpha 7$ nAChR regulates migration of monocyte-derived macrophages during acute inflammation. Journal of Neuroinflammation, 21, 3. DOI: 10.1186/s12974-023-03001-7 | PMC: PMC10765732
- [18] Environment International. (2024). PM2.5 effects on STAT3 signaling and immune cell balance.
- [19] PMC9923440. CO and aldehydes impair vagal tone in smoking.
- [20] Charaka Samhita. Pranavaha Srotas Vimana; Vyana Vayu; Prajna-aparadha. (CCRAS critical edition).
- [21] Mahto KK, Kumar M, Bhatia R, et al. (2024). Neural mechanisms of pranayama: a narrative review of autonomic, respiratory, and neurocognitive pathways. Ann Neurosci, 31(2):78-92. PMC:PMC10837615
- [22] Lehrer PM, Gevirtz R. Heart rate variability biofeedback: how and why does it work? Front Psychol. 2014;5:756. PMC:PMC4100901. [Resonance frequency 4.5–7.0 breaths/min; Mayer wave synchronization]
- [22a] Zaccaro A, Piarulli A, Laurino M, Garbella E, Menicucci D, Neri B, Gemignani A. (2018). How breath-control can change your life: a systematic review on psychophysiological correlates of slow breathing. Front Hum Neurosci, 12:353. DOI:10.3389/fnhum.2018.00353
- [22b] Acharya K, et al. (2025). Autonomic and Respiratory Modulations by Different Styles of Mantra Chanting. Ann Neurosci. PMC12181178. [Silent: LF/HF=1.11; Loud: LF/HF=2.38; n=40; Maha Mrityunjaya \times 18 rounds]
- [22c] Bernardi L, Sleight P, Bandinelli G, et al. (2001). Effect of rosary prayer and yoga mantras on autonomic cardiovascular rhythms: comparative study. BMJ. 323(7327):1446–1449. PMC60793. [Both at 6/min produced identical HRV improvements]
- [23] PMC6189422. Vagus nerve stimulation through breathing.

- [24] Vialatte FB, Bakardjian H, Prasad R, Cichocki A. (2009). EEG paroxysmal gamma waves during Bhramari Pranayama: A yoga breathing technique. *Consciousness and Cognition*, 18(4):977-988. DOI:10.1016/j.concog.2008.01.004 | PMID:18299208 [128-electrode Biosemi; LORETA; PGW left middle temporal; theta ↓ p<0.05; n=8]
- [25] Devi Chand. (1982). Translation and commentary on Atharva Veda 11.4 (Prāṇa Sūktam). In: *Atharva Veda Samhita*. Munshiram Manoharlal.
- [26] Bernardi L, Sleight P, Bandinelli G, et al. (2001). Effect of rosary prayer and yoga mantras on autonomic cardiovascular rhythms: comparative study. *BMJ*, 323(7327):1446-1449. PMC:PMC60793
- [26a] Mooventhan A, Khode V. (2014). Effect of Bhramari pranayama and OM chanting on pulmonary function in healthy individuals: A prospective randomised control trial. *Int J Yoga*, 7(2):104-110. DOI:10.4103/0973-6131.133875 | PMC:PMC4097894
- [26b] Bernardi L, Sleight P, Bandinelli G, et al. (2001). Effect of rosary prayer and yoga mantras on autonomic cardiovascular rhythms: comparative study. *BMJ*. 323(7327):1446-1449. PMC60793. [Rhythm is the medicine, regardless of content]
- [27] Kalyani BG, Venkatasubramanian G, Arasappa R, Rao NP, Kalmady SV, Behere RV, Rao H, Vasudev MK, Gangadhar BN. (2011). Neurohemodynamic correlates of OM chanting: A pilot fMRI study. *Int J Yoga*, 4(1):3-6. DOI:10.4103/0973-6131.78171 | PMC3099099 | NIMHANS Bangalore [3T fMRI; "ssss" control zero deactivation; bilateral limbic deactivation; VNS equivalence with Kraus 2007 + Henry 2004; n=12]
- [27a] Kraus T, Hosl K, Kiess O, Schanze A, Kornhuber J, Forster C. (2007). BOLD fMRI deactivation of limbic and temporal brain structures during transcutaneous vagus nerve stimulation. *J Neural Transm*, 114(11):1485-1493.
- [27b] Kanwade A, Thune N, Srimaharaj W, Chaising S, Upreti K, Jain R. (2025). Bridging science and spirituality: Investigating the effects of OM chanting on brain waves. *Sakarya University Journal of Computer and Information Sciences*, 8(4):651-663. DOI:10.35377/saucis.1692343
- [28] Mooventhan A, Khode V. (2014). Effect of Bhramari pranayama and OM chanting on pulmonary function in healthy individuals: A prospective randomised control trial. *Int J Yoga*, 7(2):104-110. DOI:10.4103/0973-6131.133875 | PMC4097894 [n=82; 10 min/day × 6 days/wk × 2 weeks; Schiller Spirovit-SP1; significant FEV₁, PEF, FEF₂₅%, MVV, SVC]
- [28a] Weitzberg E, Lundberg JO. (2002). Humming greatly increases nasal nitric oxide. *Am J Respir Crit Care Med*, 166(2):144-145. DOI:10.1164/ajrccm.166.2.164 [15-fold NO increase from nasal humming; bronchodilation mechanism]
- [29] Wen J, Sun J, Tang Y, Zhao J, Su X. (2023). Cholinergic α7 nAChR signaling suppresses SARS-CoV-2 infection and inflammation in lung epithelial cells. *J Mol Cell Biol*, 15(7):mjad048. DOI:10.1093/jmcb/mjad048 | PMID:37491690 | PMC:PMC10901198
- [29a] Chrestia JF, Olivares N, Montag D, Bhatt DL, Bhatt JM, Venter H, De Biasi M, et al. (2023). A Functional Interaction Between SARS-CoV-2 Spike and Nicotinic Acetylcholine Receptors. *Neuroscience Bulletin*. DOI:10.1007/s12264-023-01075-6 [Xenopus oocyte electrophysiology; SCoV2ED dual modulation]
- [29b] Lykhmus O, Kalashnyk O, Koval L, Krynina O, Komisarenko S, Skok M. (2022). SARS-CoV-2 Spike Protein Fragments Bind to Nicotinic Acetylcholine Receptors with Implications for Neurological Symptoms and Post-COVID Sequelae. *Biochem Biophys Res Commun*, 622:57-63. DOI:10.1016/j.bbrc.2022.07.016 | PMC:PMC9263688 [KLH immunization; α7-selective surface reduction; memory impairment]
- [29c] Russo P, Bonassi S, Giacconi R, et al. (2020). COVID-19 and smoking: is nicotine the hidden link? *Eur Respir J*, 55(6):2001116. [e-cigarette ACE2 upregulation data]
- [29d] Lippi G, Henry BM. (2020). Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). *Eur J Intern Med*. PMC:PMC7118640

- [29e] Shaaban AN, Andersson F, Magnusson C, Orsini N, Caspersen IH, Peña S, Karvonen S, Magnus P, Galanti MR. (2023). Does misclassification of former tobacco smokers explain the 'smoker's paradox' in the risk of COVID-19? Insights from the Stockholm Public Health Cohort. *Scand J Public Health*, 51(5):705-715. PMID:37165603 | PMC:PMC10183343
- [29f] UK Biobank COVID-19 cohort (~1.2M adults). PMC:PMC10208265
- [29g] Guo FR. (2020). Active smoking and severity of COVID-19. Meta-analysis 10 studies n=11,189. PMC:PMC7647838
- [29h] Rahmati M, et al. (2022). Umbrella review 27 systematic reviews: smoking and COVID-19 severity outcomes. PMC:PMC10199802
- [29i] Xu K, et al. (2024). Smoking, cross-immunity, common cold coronaviruses 229E/NL63. *Nature Scientific Reports*. DOI:10.1038/s41598-024-75632-6
- [29j] Sitapara RA, et al. (2020). GTS-21 restores hyperoxia-compromised macrophage function and reduces lung bacterial burden. *Mol Med*, 26:98. PMC:PMC7596622
- [29k] GTS-21 + IL-6 suppression in COPD macrophage model. PMC:PMC7194070
- [29l] PNU-282987/GTS-21 HMGB1 nociceptor suppression (2025). PMC:PMC12581301
- [29m] Bhatt DP, Bhatt JM, Bhatt DL, De Biasi M, et al. (2022). An experimental test of the nicotinic hypothesis of COVID-19. *Proc Natl Acad Sci USA*, 119(42):e2204242119. DOI:10.1073/pnas.2204242119 [COMPETING: Y674-R685 fragment showed no functional activation of human $\alpha 7$ nAChR in *Xenopus* system]
- [29n] Farsalinos K, Eliopoulos E, Leonidas DD, Papadopoulos GE, Tzartos S, Poulas K. (2020). Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction Between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications. *Int J Mol Sci*, 21(16):5807. DOI:10.3390/ijms21165807 | PMC:PMC7386492 [PRRA motif identification; MD docking; α -cobratoxin/ α -bungarotoxin homology]
- [29p] Bonaz B, Sinniger V, Pellissier S. (2020). Anti-inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation. *J Physiol*, 598(21):4709-4719. DOI:10.1113/JP279285 | PMC:PMC7527711 [VNS for Long COVID inflammatory component]
- [29q] Azabou E, et al. (2021). Ultrasonographic evaluation of the vagus nerve in patients with post-acute COVID-19 syndrome. *J Clin Med*, 10(24):5769. DOI:10.3390/jcm10245769 [Vagal dysfunction in Long COVID; VNS therapeutic implications]
- [30] Cosford R. (2025). Spikotherapeutics: the Cholinergic Anti-inflammatory Pathway, the Vagus Nerve and Dysautonomia: is Nicotine an answer? *Medical Research Archives*, 13(6). DOI:10.18103/mra.v13i6.6530
- [37] *Frontiers in Psychiatry*. (2025). Effectiveness of pranayama for mental disorders: a systematic review. DOI:10.3389/fpsy.2025.1616996 [Transdiagnostic vagal-dopaminergic validation; mental disorders share cessation mechanisms]
- [38] Hindawi ECAM. (2022). Yoga, Meditation, Breathing Exercises, and Inflammatory Biomarkers with Possible Implications in COVID-19: A Systematic Review and Meta-Analysis of RCTs. CRD42021283894. DOI:10.1155/2022/3523432 [IL-6 -1.44 pg/mL $p=0.002$; Cortisol -40.75 pg/mL $p=0.0006$]
- [39] Cureus. (2024). Effectiveness of Yoga in Modulating Markers of Immunity and Inflammation: A Systematic Review and Meta-Analysis. PMC11068076. [24 studies; IL-6 $n=17$; TNF- α $n=13$; CRP $n=10$; mostly significant]
- [40] PMC11778323. (2024). Impact of Short-Term Integrated Yoga Therapy Intervention: IL-6 \downarrow $p<0.001$, CRP \downarrow $p<0.01$ at 12 weeks.
- [41] PMC6883140. (2019). Benefits of yoga on IL-6: RCT findings. Yoga group: β -IL-6 = -0.24 , SE=0.09 (significant vs control which increased)

- [42] Manjunath NK. (2025). Breathing: The Master Regulator. *Adv Sleep Lab Pract*. DOI:10.4103/asl.asl_107_25 | PMC12510408 [Kumbhaka: ↑ cerebral blood flow, enhanced baroreceptor sensitivity, cardiovascular oscillations, cognitive abilities]
- [43] PMC5483482. (2017). Yoga, Meditation and Mind-Body Health: Increased BDNF, Cortisol Awakening Response, and altered inflammatory marker expression after 3-month retreat. [Yoga enhances adaptive CAR]
- [44] Mariswamy V, Kamakshi K, Kodali M, Balasubramanian K, Gangadhar BN. (2021). Effect of six months pranayama training on stress-induced salivary cortisol response among adolescents: randomized controlled study. *Explore (NY)*, 17(6):574-579. PMID:34366293
- [31] Singh S, Dhanlika D, Haldar P, Sharma G. (2025). Efficacy of yoga on tobacco cessation: A systematic review and meta-analysis. *Nicotine Tob Res*, ntaf236. DOI:10.1093/ntr/ntaf236 | PMID:41239976 | PROSPERO:CRD42025643806 | AIIMS New Delhi [7 RCTs pooled; OR=1.50 (95% CI:0.60–3.73); I²=65%; pranayama sub-group craving reduction; physical styles stress reduction]
- [32] Kumar S, Saini S, Mishra G, Baishya A, Sharma S, Hazarika D, Patra S. (2026). Volitional Yoga Breathing for Smokers: Development, Validation, and Feasibility. *Cureus*, 18(1):e101716. DOI:10.7759/cureus.101716 | PMC:PMC12914356 | Central University of Rajasthan + S-VYASA [FTND>7; FEV₁ d=1.46; urge frequency d=1.39; Nadi Shodhana CVR=1.0]
- [33] Chandra Shekar MV, Bhargav H, Holla B, et al. (2025). Development, validation and feasibility testing of Y-BLISS module. *J Family Med Prim Care*, 14(6):2502–2513. DOI:10.4103/jfmpc.jfmpc_1980_24 | PMC:PMC12296329 | NIMHANS + Harvard + S-VYASA [12-min module; BYPP; FTND reduction F(2,14)=13.93 p<0.01; PEFR F(2,14)=20.39 p<0.01; CPD –19.8%]
- [34] Bock BC, Fava JL, Gaskins R, et al. (2019). Yoga as a complementary therapy for smoking cessation: Results from BreathEasy. *Nicotine Tob Res*, 21(11):1517. DOI:10.1093/ntr/nty212 | PMC:PMC6821291 | Brown University [n=227; 37% relative quit increase longitudinal; light smokers >2× quit rate; heavy smokers –2.66 CPD]
- [35] Lotfalian S, Spears CA, Juliano LM. (2020). Effects of mindfulness-based yogic breathing on craving, affect, and smoking behavior. *Psychol Addict Behav*, 34(2):351–359. DOI:10.1037/adb0000536 | PMC:PMC7064378 [3-arm RCT n=60; only MB group showed significant craving reduction + reduced smoking in choice procedure]
- [36] *Front Psychiatry*. (2022). Yoga vs. Aerobic Exercise for smoking cessation: ERP comparison. PMC:PMC9334723 [Both yoga and aerobic reduced negative affect; craving reduction ONLY after yoga – NOT after aerobic exercise; N2, P3 ERP confirmed neural mechanism differences]

Vedic Primary Sources

- [BG] Bhagavad Gita. Chapter 2, Verse 50 (Yogaḥ karmasu kauśalam). Chapter 2, Verse 48 (Samatvaṃ yoga ucyate). Chapter 2, Verse 47 (Karmanṃ evādhikāras te). Chapter 4, Verse 29 (Prāṇāyāma-parāyaṇaḥ). Chapter 3, Verse 37 (Kāma eṣa krodha eṣa). Tr. Swami Gambhirananda. *Advaita Ashrama*, 1997. [Primary philosophical source – Yoga definition; Nishkama Karma cessation protocol; Pranayama as yajña]
- [YS] Patañjali. *Yoga Sūtras*. YS 1.2 (Yogaḥ citta-vṛtti-nirodhaḥ). YS 1.6 (Pañca Vṛttis). YS 1.12 (Abhyāsa-vairāgyābhyāṃ tan-nirodhaḥ). YS 2.1 (Kriyā Yoga triad: Tapaḥ-svādhyāya-īśvarapraṇidhānāni). YS 2.29 (Aṣṭāṅga Yoga). Tr. Swami Vivekananda. *Rāja Yoga*, 1896. [Primary source – Yoga definition; Five Vṛttis taxonomy; Eight limbs hierarchy]
- [CS] Caraka Saṃhitā. Sūtrasthāna 7.52 (Prajñāaparādho hi mūlaṃ rogaṇām – Prajñā-aparādha as root of disease). *Cikitsāsthāna* 28 (Pañca Vāyu). *Vimānasthāna* 5 (Prāṇavaha Srotas). Tr. P.V. Sharma. *Chaukhamba Orientalia*, 2001. [Primary Ayurvedic source – Pranavaha Srotas; Pancha Vayu; Prajna-aparadha]
- [AV] Atharva Veda 11.4 (Prāṇa Sūktam). 26 mantras. Tr. Devi Chand. *Munshiram Manoharlal*, 1982. [Primary mantra source – Prana as master of all physiology]

Upanishadic Primary Sources

[BU] Bṛhadāraṇyaka Upaniṣad. 1.5.3 (prāṇo vā amṛtam — Prana is immortality). Tr. Swami Madhavananda. Advaita Ashrama, 1950. [CAP as the body's immortality system; Vedic anticipation of anti-inflammatory pathway]

[CU] Chāndogya Upaniṣad. 7.15.1 (prāṇo hi pitā prāṇo mātā... — Prana is father, mother, brother, sister, teacher, Brahman). Tr. Swami Gambhirananda. Advaita Ashrama, 1983. [Systems biology description; α 7 nAChR maintains both Chat and Adrb2 — cross-pathway dependency predicted 2,500 years before Merchant 2025]

[PU] Praśna Upaniṣad. Adhyāya 2 (Dvitiya Praśna — The Prana Chapter). 2.3 (prāṇo rakṣati garbham — Prana protects the being like a mother her child). Tr. Swami Gambhirananda. Advaita Ashrama, 1984. [Pancha Vayu teaching from Rishi Pippalāda to Bhārgava; maternal surveillance function of CAP]

[KU] Kena Upaniṣad. 1.2 (yad vācā 'nabhyuditaṃ yena vāg abhyudyate — That which speech cannot express but by which speech is expressed). Tr. Swami Gambhirananda. Advaita Ashrama, 1984. [Silent Manasika Japa operates at pre-verbal Brahman level — why silent chanting is more effective for craving than loud]

[MU] Māṇḍūkya Upaniṣad. Mantras 3-7 (Jāgrat, Svapna, Suṣupti, Turīya). Mantra 7: prapañcopaśamaṃ śāntaṃ śivam advaitaṃ caturtham — The fourth is peaceful, auspicious, without a second. Tr. Swami Nikhilananda. Ramakrishna-Vivekananda Center, 1949. [Consciousness states parallel to receptor states; nic₀ = Suṣupti mistaken for Turīya; authentic recovery = S3 = Turīya]

[TU] Taittirīya Upaniṣad. Brahmananda Valli 2.2–2.5 (Pañca Kośa — Five Sheaths). 2.2 Annamaya; 2.3 Prāṇamaya; 2.4 Manomaya + Vijñānamaya; 2.5 Ānandamaya. Tr. Swami Gambhirananda. Advaita Ashrama, 1986. [Five sheaths model; smoker seeks Ānanda through counterfeit; complete addiction taxonomy]

[IU] Īśā Upaniṣad. Mantra 1 (īśā vāsyam idaṃ sarvam... tena tyaktena bhuñjithā — All this is pervaded by the Lord; enjoy through renunciation). Tr. Swami Chinmayananda. Central Chinmaya Mission Trust, 1969. [Cessation through renunciation, not suppression; Lobha (greed) as Shadripu root; BG 2.47 parallel]

Vedic Scholarship References

[S1] Singleton M. (2010). Yoga Body: The Origins of Modern Posture Practice. Oxford University Press. ISBN:978-0195395358 [Historical: modern postural yoga = 20th century synthesis of traditional āsana with European gymnastics; Krishnamacharya Mysore Palace; Iyengar/Pattabhi Jois export; 89% of "yoga" RCTs test āsana-dominant interventions, not Vedic Yoga]

[S2] PMC4959332. (2016). From Yama to Samyama: A theoretical framework connecting Patañjali's eight limbs to psychophysiological wellbeing. [Aṣṭāṅga Yoga clinical mapping; Limbs 1–8 mechanism hierarchy; Limb 3 (Āsana) = stress reduction; Limbs 4–7 (Prāṇāyāma–Dhyāna) = craving cessation]

[S3] PMC3705674. (2013). Karma Yoga: A path towards work in positive psychology. Indian Journal of Positive Psychology. [Nishkama Karma applied to behavior change; BG 2.47 as cessation framing; practice-focused vs. outcome-focused motivation]

Appendix A: Prana Suktam (Atharva Veda 11.4) — Complete Sanskrit Text

॥ प्राण सूक्तम् ॥

१। प्राणाय नमो यस्य सर्वमिदं वशे। यो भूतः सर्वस्येश्वरो यस्मिन्सर्वं प्रतिष्ठितम्॥

२। नमस्ते प्राण क्रन्दाय नमस्ते स्तनयिन्ने। नमस्ते प्राण विद्युते नमस्ते प्राण वर्षते॥

३। यत्प्राण स्तनयिन्नुना अभिक्रन्दत्योषधीः। प्र वीयन्ते गर्भान्दधते अथो बहिर्वि जायन्ते॥

४। यत प्राण ऋतवागन्ते अभिक्रन्दत्योषधीः। सर्वं तदा पर मोदते यत्किं च भूम्यामधि॥

५। यदा प्राणो अभ्यवर्षद्विर्वेषेण पृथ्वीं महीम्। यशवस्तत्र मोदन्ते महो वै नो भविष्यति॥

६। अभिवृष्टा ओषधयः प्राणेन संवादिरन्। आयुर्वै नः प्रातीतरः सर्वा नः सुरभीरकः॥

७। नमस्ते अस्त्रायते नमो अस्तु परायते। नमस्ते प्राण तिष्ठत आसीनायोत ते नमः॥

- ८। नमस्ते प्राण प्राणते नमो अस्तु अयानते। पराचीनाय ते नमः प्रतीचीनाय ते नमः सर्वस्मै त इदं नमः॥
- ९। या ते प्राण प्रिया तनूर्यो ते प्राण प्रेयसी। अथो याद् भेषजम् तव तस्यं नो धेहि जीवसे॥
- १०। प्राणाः प्रजा अनु वस्ते पिता पुत्रमिव प्रियम्। प्राणो ह सर्वस्येश्वरो यच्च प्राणति यच्च न॥
- ११। प्राणो मृत्युः प्राणस्तक्त्वा प्राणं देवा उयासते। प्राणो ह सत्यवादिनमुत्तमे लोक आ दधत्॥
- १२। प्राणो विराट् प्राणो देही प्राणं सर्वे उयासते। प्राणो ह सूर्यश्चन्द्रमाः प्राणमाहुः प्रजापतिम्॥
- १३। प्राणायानौ ब्रीहियवावनडवान् प्राण उच्यते। यवे ह प्राण आहितो अयानो ब्रीहिरुच्यते॥
- १४। अयानति प्राणति युरुषो गभ्रे अन्तरा। यदा त्वं प्राण जिन्वसि अथ स जायते युनः॥
- १५। प्राणमाहर्मातरिश्वानं वातो ह प्राण उच्यते। प्राणे हं भूतं भव्यम् च प्राणे सर्वं प्रतिष्ठितम्॥
- १६। आथर्वणीर् आंगिरसीर् देवीर् मनुष्यजा उत। ओषधयः प्र जायन्ते यदा त्वं प्राण जिन्वसि॥
- १७। यदा प्राणो अभ्यवर्षीर्षेण पृथ्वीं महीम्। ओषधयः प्र जायन्ते अथो याः काश्च विरुधः॥
- १८। यस्ते प्राण इदं वेद यस्मिंश्चासि प्रतिष्ठितः। सर्वे तस्मै बलिं हरान् अमुर्भिल्लोक उत्तमे॥
- १९। यथा प्राण बलिहृतस्तुभ्यं सर्वाः प्रजा इमाः। एवा तस्मै बलिं हरान् यस्त्वां शृणवत् सुश्रवः॥
- २०। अन्तर्गर्भश्चरति देवतास्व आभूतो भूतः स उ जायते युनः। स भूतो भव्यं भविष्यत् पिता पुत्रं प्र विवेश शचीभिः॥
- २१। एकं यादं नोत् खिदति सलिलाद्धंस उच्यरन्। स भूतो भव्यं भविष्यत् पिता पुत्रं प्र विवेश शचीभिः॥
- २२। अष्टाचक्रं वर्तत एकनेत्रे सहस्राक्षरं प्र युरो नि यक्षा। अर्धेन विश्वं भुवनं जजान यदस्यार्धं कतमः स केतुः॥
- २३। यो अस्य विश्वजन्मन ईशे विश्वस्य चेष्टतः। अन्येषु क्षिप्रधन्वने तस्मै प्राण नमोस्तु ते॥
- २४। यो अस्य सर्वजन्मन ईशे सर्वस्य चेष्टतः। अतन्द्रो ब्रह्मणा धीराः प्राणो मानुम् तिष्ठतु॥
- २५। ऊर्ध्वः सुप्तेषु जागार न तिर्यङ् नि पद्यते। न सुप्तस्य सुप्तेषु अणुं शुश्राव कश्चन॥
- २६। प्राण मां मत्पर्यावृतो न मदन्यो भविष्यसि। अपाम् गभ्रमिव जीवसे प्राण बन्धनामि त्वा मयि॥

Key Mantra Meanings for Cessation Protocol

Mantra	Trigger State	Meaning
1	Morning sankalpa	"Reverence to Prana in whose control all exists"
7-8	Social trigger	"Salutation to Prana coming and going, in all directions"
9	Craving peak	"O Prana, give us your medicine that we may live"
15	Anxiety/future worry	"In Prana alone past and future are established"
26	Lapse recovery	"O Prana, bind me within you as life lives in water's womb"

Appendix B: Isha Upanishad Shanti Mantra

ॐ पूर्णमदः पूर्णमिदं पूर्णात् पूर्णमुदच्यते। पूर्णस्य पूर्णमादाय पूर्णमेवावशिष्यते॥

Om pūrṇamadaḥ pūrṇamidam pūrṇāt pūrṇamudacyate pūrṇasya pūrṇamādāya pūrṇamevāvaśiṣyate

Translation: "That is complete. This is complete. From completeness, completeness arises. When completeness is taken from completeness, completeness alone remains."

Relevance to Pranavaha: Even when Rahu (nicotine, lapse, industry) takes from you, Prana alone remains. The wholeness of the system cannot be destroyed — only obscured. Practice reveals it again.

जय श्री कृष्ण। हर हर महादेव।

Draft Version 1.0 – 15 March 2026 arXiv Categories: q-bio.NC (Neurons and Cognition), q-bio.TO (Tissues and Organs)
Intended Preprint Servers: arXiv, bioRxiv